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CHAPTER I 
 
INTRODUCTION 
 
The war on cancer is approaching its 40 year anniversary, and yet cancer 
remains the 2nd leading cause of death in the US.  Our understanding of the disease 
has increased tremendously over these years.  Insights into viral driven cancers, 
hereditary and environmentally acquired genomic mutations, oncogenic protein 
pathways, and recently the mapping of the human genome1 have improved our 
understanding of cancer biology, treatments, and prognosis.  Breakthrough cures, such 
as Gleevec for chronic myeloid leukemia (CML) patients, however, remain rare 
occurrences.2   
The sharp contrast between the tremendous steps forward in cellular biology and 
the limitations of current treatment regimes underscores the enormous challenge we 
face.  Cancer as a disease is truly complex, as the same type of cancer can arrive by a 
completely different set of mutations, and a single cancer may be composed of a 
heterogeneous population of cells, each containing different acquired mutations and 
resistance to treatment.   As we uncover more specifics on the causes and the players 
involved  in the hallmarks of cancer, such as the mechanisms of evading the immune 
system, metastasis, recruitment of blood supply, and autocrine growth, we can continue 
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to develop more effective targeted therapies and optimize treatment regimes for the 
individual patient.3    
For many cancers clinicians have limited and crude tools available to accurately 
distinguish tumor subtypes, including melanoma where staging and stratification 
predominantly rely on tumor size, presence of ulceration, and depth of invasion.  
Patients presenting with advanced melanoma have a grim outcome and the majority of 
late stage patients will ultimately die from the disease.  A need exists to develop 
molecular markers to categorize the heterogeneity of melanoma tumors for diagnosis, 
prognosis, and potential treatment efficacy to improve the resources clinicians have for 
patient evaluation and treatment.    
The purpose of this work is to describe metastatic melanoma using modern mass 
spectrometry technology in order to understand and characterize proteins involved in 
the disease for diagnosis, prognosis, and molecular classification.  A sufficient 
understanding of melanoma, its causes and progression, as well as the mechanisms of 
mass spectrometry (MS) in the scope of proteomics is crucial.  The following is 
presented as an orientation in these areas.   
 
Melanoma 
 
Melanoma is the deadliest form of skin cancer, contributing to over 80% of skin 
cancer mortalities.  The disease arises when melanocytes, the melanin (pigment) 
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producing cells found in the skin, begin to grow uncontrollably.  Despite an 
overwhelming amount of research and increased public awareness, melanoma 
accounted for an estimated 62,000 new cases and 8,400 deaths in 2008 in the U.S. 
alone. 4   
Beginning as neural crest cells, melanoblasts migrate to the skin during 
development and differentiate into melanocytes, where they exist singly distributed 
along the basal layer between the dermis and epidermis.  Here, keratinocyte cells from 
the epidermis and fibroblasts from the dermis surround and regulate the isolated 
melanocytes, and upon exposure to UV damage, induce the melanocytes to produce 
and distribute melanin to surrounding cells.5  The predominant mechanism for this is 
through keratinocytes producing α-melanocyte-stimulating hormone (α-MSH) that binds 
to melanocortin 1 receptor (MC1R) on the melanocytes, triggering micropthalmia-
associated transcription factor (MITF) stimulating melanosome (melanin containing 
“packages”) production and transportation to keratinocytes by dendritic processes.6 
Under normal conditions, the melanocytes grow very slowly and are very resistant to 
apoptosis, as the cells are responsible for mounting the defense after UV damage.  This 
resilience no doubt contributes to advanced melanoma‟s high resistance to adjuvant 
therapy. 
The risk factors for melanoma include the presence of benign nevi (i.e. moles), 
family history of melanoma, fair skin, and a history of severe sunburns.7  Ultraviolet (UV) 
light is directly harmful to cells, by way of producing oxidative species that damage DNA 
and by direct DNA damage (cyclobutane pyrimidine dimmers and 6,4-photoproducts).  
Interestingly, it is periods of intense intermittent UV exposure to under-protected skin 
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(so-called “recreational sun”) that induces the most DNA damage. Chronic exposure to 
UV creates a lasting melanin response and is associated with a lower risk for 
melanoma.8, 9   
Melanoma, like any cancer, requires a certain number of mutations to occur 
before the full onset of uncontrolled melanocyte growth.  Inherited susceptibility, such as 
a genetic defect in CDKN2A or the limited melanin production in light-skinned and 
redheaded populations reduce the skins defense against UV damage.  Environmental 
factors, mainly UV damage, likely contribute to the remaining mutations.  One simplified 
model for the progression from normal, controlled melanocytes to melanoma is through 
a set of steps, starting with benign nevus, progressing to dysplastic nevi, to early stage 
cancer as radial-growth phase (RGP), and progressing to invasive vertical growth phase 
(VGP) before finally metastasizing to a distant location, Figure 1.   In reality, most 
benign nevi and dysplastic nevi will never develop into melanoma, but instead show a 
set of acquired mutations that indicate a higher susceptibility for melanoma.  
Furthermore, vertical growth phase melanoma may appear in the absence of previous 
benign nevi.  In effect, several mutations along key molecular pathways are required for 
melanoma. 
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Diagnosis and Staging 
Melanoma is divided into several clinical subtypes: nodular, acral lentiginous 
(ALM), lentigo maligna, and superficial spreading melanoma (SSM).10  Nodular 
melanoma forms raised nodules with limited flat portion and is associated with high risk 
due to rapid proliferation and significant dermal invasion.  ALM is the most common 
form found in non-Caucasian populations and is found in the palms, soles of the feet, 
and nail beds, but is not associated with UV exposure.  Lentigo maligna occurs most 
often on the face and neck of elderly populations and appears as large “liver spots”.  
SSM is by far the most common and is associated with severe sunburns and appears 
most commonly on recreational sun exposure sites. 
Primary melanoma is diagnosed visually based on the size, shape, and color of the 
growth.  This is known as the ABCD‟s of melanoma:  
A) Asymmetry: the lesion has an irregular, non-circular shape  
B) Border: the edge of the lesion is irregular, blurred or ragged 
C) Color: the lesion is composed of various, non-uniform shades of black or brown 
D) Diameter: greater than 6 mm or rapidly changing in size 
Advanced metastatic disease may additionally require immunohistochemistry 
(IHC) staining to accurately diagnose, typically with a combination of S100 and 
MART1/HMB-45.11  As metastatic disease progresses, melanoma cells often de-
differentiate and cease producing melanin, consequently IHC validation is required to 
confidently identify the tumor as melanoma.  
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Staging of melanoma was established by the 2002 American Joint Committee on 
Cancer (AJCC) Melanoma Staging Committee.12  Stage I and II disease describe local 
primary tumor, stage III classifies regional metastasis (usually to the regional lymph 
nodes), and stage IV disease encompasses distant metastasis.  All 4 stages use the 
TNM (T:tumor, N:nodal, M:metastasis) classification.  Table 1 shows the important 
criteria for each of these stages and the associated 5 year survival.13  Clinical and 
pathological prognostic factors for survival of patients include tumor thickness, 
ulceration and mitotic rate of the primary tumor, and the number and size of involved 
lymph nodes.   
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Diagnosis of stage III disease is accomplished through the use of an elective 
lymph node dissection (ELND) or sentinel lymph node (SNL) biopsy.  The SNL 
technique injects a blue dye (1% isosulfan blue) and a radioisotope (technetium Tc 99m 
sulfur colloid) around the primary tumor to find the first draining lymph node.  This “blue” 
node is excised and sent to pathology for analysis.  A positive lymph node (confirmed 
with S100 and MART1/HMB45) will elicit a complete lymph node dissection.  A positive 
lymph node is found in approximately 20% of patients possessing primary tumors > 
1mm with drainage to more than 1 lymph node in 15% to 27% of patients.14  Patients 
with stage III disease or who are symptomatic should undergo advanced imaging with 
MRI, PET, and/or CT scans to determine stage IV disease. 
 
Molecular Pathways of Melanoma 
Tumorigenesis of melanoma arises as proteins (oncogenes) along key regulatory 
pathways become altered in function.  These molecular pathways are complex signaling 
highways that control cellular functions, such as cell growth, differentiation, senescence, 
cellular and DNA repair, cell adhesion and migration, and cell-cell communication, 
Figure 5.  Many of these networks contain “check-points” in the form of proteins whose 
function determines whether a cellular process begins or halts.  These alterations 
include pathway regulators that are hyperactivated or over/under expressed.  Several of 
the pathways and common alterations pertaining to melanoma are described. 
The mitogen-activated protein (MAP) kinase cascade controls cell proliferation 
and differentiation based on detection of external growth factors, Figure 2.  External 
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growth factors, such as epidermal growth factor (EGF) or platelet-derived growth factors 
(PDGF), bind to their respective cell surface receptors (i.e. EGF-R and PDGF-R) 
phosphorylating the intracellular portion of the receptor, activating a binding site for 
growth factor receptor-bound protein 2 (Grb2)-SOS complex.  Once bound to the 
receptor, SOS is activated and promotes GDP removal from Ras, allowing Ras to bind 
GTP and activate Raf which in turn activates the MEK1/2 complex.  MEK1/2 can then 
activate the ERK1/2 (a.k.a. MAPK) complex leading to activation of c-MYC which 
activates cell proliferation.   
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In melanoma, BRAF mutation is the most frequently observed; present in up to 
80% of all melanomas.  The most common mutation, in 80% of mutated BRAF cases, is 
a single V E substitution at residue 600 that dramatically increases its activity, 
effectively turning on the MAPK pathway.15, 16 BRAF mutation is present in most benign 
nevi, indicating it alone is insufficient for complete melanoma transformation.   In the 
MAPK pathway, mutation in NRas is also observed in ~10% of cases, is tied to UV 
exposure, and is notably mutually exclusive to the b-Raf mutation, due to the overlap of 
oncogenic function of both along the MAPK pathway.  The overwhelming presence of 
BRAF mutation prompted focus for inhibitors in patient treatment. 
Numerous other pathways have been implicated in melanoma.  The PI3K-Akt 
pathway is involved in cellular survival specifically by inhibition of apoptosis, gain of 
function mutations are observed in melanoma.  Several motility proteins that tether and 
foster cell-cell communication have been seen in melanoma, including B-catenin, 
VCAM, and ICAM.  Beyond BRAF and NRAS mutated activation of MAPK, melanoma 
cells can increase both the production of growth factors and the number of growth factor 
receptors.  Finally, in gaining the ability to metastasize, melanoma cells excrete an 
increased level of MMP that degrade the surrounding ECM.17  
 
Treatment 
Complete surgical excision of all gross disease remains the best option for 
patients.  Patients with primary disease are routinely cured by resection alone, though 
follow-up and investigation of future symptoms is highly recommended.  However, 
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surgical resection alone is insufficient in patients diagnosed with stage III disease, as 
half of them will eventually die from the disease.  Melanoma remains notoriously 
resistant to adjuvant and systemic therapy, being widely viewed as both chemoresistant 
and radioresistant.  While novel therapeutics show signs of relapse-free survival, the 
benefit to overall survival has yet to be definitively shown. 
Currently, only interferon alfa 2b (IFN-α2b) has been approved by the Food and 
Drug Administration (FDA) for the treatment of high risk melanoma patients.  
Unfortunately, the treatment is associated with significant side effects and analysis of 
clinical trials E1684, E1690, E1694, and E2696 showed a benefit to relapse-free-
survival, but no benefit to overall survival.18  For stage IV melanoma, the FDA has 
approved only dacarbazine and interleukin-2 (IL-2), neither resulting in a clinically 
meaningful improvement in overall survival.  Dacarbazine, along with the orally 
administered form temozolomide, have shown response rates from 13-22% without a 
benefit to overall survival.19, 20  IL-2 is a recombinant hormone that stimulates the 
immune system by activation of cytotoxic T cells.  IL-2 has shown a long term durable 
response in a small set of patients (5%), but the treatment is associated with significant 
toxic effects, in which some cases required intensive care support.21  Currently, there is 
no known system for selecting patients who show this long term response.  
Novel treatments for melanoma are being developed that target specific 
antigens, receptors, or transduction pathways.  These include BRAF, Raf kinase, Bcl-2, 
Kit, NF-κB, and the angiogenesis inhibitor for VEGF.14, 22, 23  Therapy combinations are 
being investigated and provide indications that a multimodal approach will improve 
efficacy and allow more individualized treatment strategies.  However, these 
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approaches remain largely unsuccessful in providing survival benefits to patients.  
Clearly there is a need for research into additional therapeutic targets. 
 
Modern Proteomics 
 
Understanding the complex nature of numerous interacting proteins in cancer 
and other diseases is due in large part to the development of proteomics and proteomic 
technologies.  Proteomics is the focused study of proteins, in particular their structure, 
function, and quantity on a global scale.  The global expression of proteins within a cell 
determines nearly every behavior, function, and interaction within and in conjunction 
with other cells.  In contrast to a static genome, the proteome is expressed differently 
from cell to cell and from time to time.  In addition to this fluctuation, proteins range in 
size from a few kDa to several MDa and can differ by 6 orders of magnitude in 
concentration.  A protein may further undergo any number of post-translational 
modifications (PTMs) or form complexes with other proteins which may dramatically 
alter its function.  Clearly proteomics remains one of the most important and analytically 
challenging feats of our time.   
Experimental procedures for large-scale global proteome analyses typically 
examine the difference in expression of hundreds of proteins between two or more 
biological states.  The objective is to understand protein alterations resulting either 
directly or indirectly from a biologic process.  Proteomic differences are expected to be 
present, for example, between benign and invasive disease, brains from Alzheimer‟s 
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patients, as well as between native tissue and those exposed to pharmaceuticals or 
toxins.  Proteins that differ between biological states can then be studied to understand 
the nature of a disease or the effect of a drug.  In many cases, these differentially 
expressed proteins may become potential biomarker candidates and eventual 
therapeutic targets.   
Proteomics is fundamentally reliant on the power of mass spectrometry (MS) for 
rapid and specific protein analysis.   Mass spectrometry involves three basic 
components: ionization, mass separation, and detection.  The gas-phase analyte, M, 
must be charged, typically via: 
(1) M + H+  [M+H]+ or M + xH+  [M+nH]n+ 
Electric and/or magnetic fields manipulate and separate ions by their mass-to-charge 
(m/z) ratio.  Once separated, the ions are detected, typically by collision into an electron 
multiplier device.  The result is a display of the measured intensity vs. the m/z value for 
all ions detected.  Two ionization methods have revolutionized proteomics by allowing 
the direct soft ionization of large protein molecules and appropriately shared the Nobel 
Prize in chemistry in 2002.  Electrospray ionization (ESI) and matrix-assisted laser 
desorption/ionization (MALDI) instruments are now the core of proteomics workflows.24   
 
Current Proteomic Technologies 
Large scale approaches to characterize the proteome generally fall under two 
categories, gel-based separation of intact proteins (pseudo top-down) and 
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multidimensional liquid chromatography (LC) of digested proteins (bottom-up).  Both of 
these technologies require the sample to be homogenized into a solution form, 
effectively removing any spatial information.  Gel electrophoresis, which separates 
proteins by their molecular weight (MW) in 1-dimension or by their isoelectric point (pI) 
and MW in 2-dimensions, produces an easily visible map of the proteins in the sample.  
Protein “maps” are compared between biological states to find specific protein 
differences between groups.25, 26  Multiple samples can be labeled with fluorescent tags 
and analyzed simultaneously on a single gel using 2D difference in-gel electrophoresis 
(2D-DIGE).27  Proteins contained in the spots are digested, extracted, and analyzed by 
LC-tandem MS or confirmed by immunoblotting.  The clear advantage afforded is the 
ability to visualize a map of numerous intact proteins, and to then positively identify 
them.  Multiplex and scaling complications keep 2D gel technology “low-throughput” and 
analysis of each protein spot, even when automated, can be both laborious and time 
consuming.  
In the other approach, liquid chromatography is extensively used to reduce the 
complexity of complex biological samples prior to MS analysis.  In the “shotgun-
proteomics” approach (also termed multidimensional protein identification technology 
MudPIT),28 all of the extracted proteins are enzymatically digested together to form a  
more complex peptide mixture.  The peptides are then separated in two dimensions, 
typically using strong cation/anion exchange (SCX/SAX) followed by reverse-phase 
(RP) LC. The eluent from the second separation goes directly into the mass 
spectrometer for peptide identification.  While it may seem that initial digestion of the 
intact proteins further convolutes an already complex mixture, the speed at which this 
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analysis can be done is much faster than for the 2D DIGE approach.  Also, peptides are 
more easily separated and identified than intact proteins.  This platform has been driven 
in large part by tremendous advances ion trap technology29 and in the construction of 
genomic-based protein databases30 and advanced algorithms to search and identify 
peptides and their precursor protein.31  Comparison of biological states can be 
accomplished by relative quantitation of peptides between separate analyses using 
spectral counting32, 33  or by direct comparison of isotopically labeled peptides, such as 
ICAT34 or iTRAQ35, from a single run. Despite the overwhelming strengths and its 
widespread use, bottom-up proteomics suffers from describing intact biologically active 
proteins, resulting in limited concrete evidence for intact protein character and function.   
 
MALDI Imaging MS of Biological Tissues 
 
Matrix-assisted laser desorption/ionization (MALDI) imaging mass spectrometry 
(IMS) of intact proteins records and combines proteomic data with location information 
directly from thin sections of biological samples.36, 37  The spatial integrity of the proteins 
within the biopsy section is maintained, allowing specific cellular regions to be analyzed.  
For the analysis, matrix is applied uniformly or in a discrete grid array across the tissue, 
Figure 3.  A laser irradiates the matrix and ionizes the proteins, generating 2 
dimensional data containing both the proteins detected and the tissue location.  The 
sampling positions become „pixels‟ that are compiled to generate a picture or image for 
each molecule detected. Any given mass-to-charge (m/z) signal in the spectrum can be 
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displayed with its relative intensity over the entire array, giving a density map of that 
compound in the array area.  Hundreds of such pictures or images can be generated 
from a single acquisition experiment.    
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MALDI IMS for proteomics has the benefit of 1) measuring intact proteins with 
high mass accuracy (typically better than 1 part in10,000), 2) measurement of intact 
proteins in their native, biologic state including PTM‟s, 3) in-situ analysis directly from 
tissue with location and cellular specific information and, 4) high sensitivity of intact 
proteins below 20 kDa (an area often overlooked in other proteomic analyses).  MALDI 
IMS has been employed to generate ion density maps (images) of numerous detected 
analytes, including pharmecueticals38-41, lipids42, enzymatically cleaved proteins43, and 
intact proteins44-47.   
This technology has also been used to identify biomarkers and classifiers for 
clinical diagnosis and potential treatment of cancer,48 including lung cancer49, gliomas50, 
and breast cancer51.  The technology has recently been adapted to accurately target 
small cellular regions within tissue biopsies, termed histology-directed IMS where a 
pathologist examines a histological stained tissue section to guide and confidently target 
the cellular regions of interest in an adjacent serial section of the biopsy, Figure 4.52  In 
this way, the proteins from tumor foci or regions of adjacent “normal” tissue can be 
analyzed from each section, and necrotic, autolysis, connective tissue, and blood 
vessels can be avoided, so as not to unduly complicate the analysis.    
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MALDI TOF Fundamentals 
Advances in interface technology have allowed MALDI and ESI sources to be 
coupled to virtually any mass analyzers, including quadrupole, ion trap, time-of-flight 
(TOF), Fourier transform ion cyclotron resonance (FT-ICR), and more recently orbitrap 
instruments.  MALDI TOF composes the core of our MS workflow and is described here 
in some detail. Detailed descriptions of other MS configurations can be found here.* 
Matrix-assisted laser desorption/ionization (MALDI) was developed from the work 
of Karas, Hillenkemp, and Tanaka during the late 1980‟s.53, 54  The technology uses a 
light absorbing molecule, or matrix, to desorb and ionize analytes, with relatively little 
fragmentation.  An analyte is co-mixed with a solution of dissolved matrix, applied to a 
conductive target plate, and as the solution dries, the matrix forms a crystal lattice that 
incorporates the analyte.  When the crystals are irradiated with a UV laser, the photons 
are absorbed by the crystals and the energy transformed into kinetic energy Ek. This 
energy conversion creates a matrix “plume” that converts the analyte into the gas phase 
and ionizes them, Figure 5.55  Suitable matrix molecules are often small, acidic aromatic 
compounds, such as the common 3,5-dimethyoxy-4-hydroxycinnamic acid (sinapinic 
acid, SA), α-cyano-4-hydroxycinnamic acid (CHCA), and 2,5-dihydroxybenzoic acid 
(DHB).  
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The explosion from the MALDI process produces ions with a mix of kinetic 
energy, Ek. A small time delay (~200 ns) from the laser irradiation is applied, termed 
delayed extraction.  When the extraction grid is activated and an electric field 
accelerates the ions, those farther from the source will receive a slightly lower push.  
The exact time delay is adjusted to spatially focus the ions on the detector.   
Ions are typically accelerated 20-25 kV into the TOF, Figure 3, which consists 
of a hollow field-free tube usually less than a meter in length.  The ion separation is a 
function of the basic principles of a charged particle in an electric field: 
(1)  
where Ep is the potential energy, q is the charge on the particle, and U is the strength of 
the electric field or voltage applied.  With no hinderance on the ions, the poteintial 
energy is converted to kinetic,  Ep  = Ek , and is given by 
(2) Ek =  
where m is the mass and v is the ion velocity, and by substitution becomes 
(2)  =  
The ion velocity is the ratio of the length of the flight tube d and the flight time of the ion 
t, giving 
(3)  
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And by substitution with equation (3),  
(4)  =  
Solving for t, we obtain 
(5)  
With d and U constant, a constant k simplifies equation (6) to 
(6)  
Thus, the flight time is inversely proportional to the mass and more specifically, to m/z 
(where q becomes z).  Larger ions will have a longer flight time, and thus reach the 
detector after smaller ions.  
Modern MALDI instruments are incredibly fast, routinely acquiring 1000 or more 
spectra per second.  Unlike ESI, MALDI produces almost exclusively singly charged 
ions, making spectral interpretation straightforward.   
 
Recent MALDI IMS Developments 
Several technological advances in recent years have dramatically improved the 
workflow, robustness, and image quality of MALDI IMS in matrix deposition, data 
acquisition, and image processing and analysis.  Previously reported robotic deposition 
by a prototype acoustic spotter56 was limited to ~200 µm lateral spot resolution.  Current 
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versions continuously move the target with constant droplet ejection, providing lateral 
resolution of 150 µm while reducing spotting time.  Controlled mechanical spray 
deposition controls the humidity, measures matrix drying, and generates smaller 
droplets by advanced vibrational vaporization spray.57  Further, matrix deposition by 
sublimation58 coats an entire tissue with uniform sub micron crystals in less than 10 
minutes, with images under 30 µm lateral resolution.  Although sublimation is currently 
limited to endogenous lipid analysis, recrystallization of the coating is proving successful 
for higher mass analytes. 
Optimal protein analysis via MALDI has been limited to N2 lasers and as a 
consequence, 20-50 Hz spectral acquisitions and 20 million shot lifetimes.  Modulation 
of Nd:YAG lasers give comparable or superior protein spectra at laser speeds of 1 kHz 
and lifetimes of more than a billion laser shots.59  Prototype instruments incorporating 5 
kHz lasers are currently being investigated.  In conjunction, image processing software 
integrates spectral processing, image processing, image visualization, and statistical 
analyses of image regions [ClinProt Ref].  These advances combine to significantly 
improve the ease, quality, speed, and analysis of MALDI IMS.   
MALDI TOF IMS and the histology-directed MALDI IMS adaptation are here used 
as the proteomic technology to investigate the biology of metastatic melanoma.   
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Thesis Objectives 
The purpose of this research is to achieve the following objectives: 
Objective 1: Determine specific proteins that distinguish cancer free lymph nodes from 
melanoma infiltrating lymph node.  From the proteins, develop robust molecular 
classifiers that distinguish the two tissue types. 
 
Objetive 2: Determine proteins that correlate with survival and disease recurrence in 
patients with stage III melanoma to distinguish aggressive from less aggressive 
disease.  From the significant proteins, develop predictive molecular classifiers and 
determine effectiveness. 
 
Objective 3:  Apply enzymatic digestion to formalin-fixed melanoma tissue microarrays 
for diagnostic and classification markers of disease.  Integrate MALDI IMS of FFPE 
tissue with histology using MITF. 
 
Adaptation of current on tissue MALDI IMS technology to melanoma tumors, both 
fresh frozen and formalin-fixed, was required to meet these objectives.  For adequate 
biological analysis of the significant proteins, the m/z values were identified with their 
PTMs observed in their particular biological state.  Pairing significant protein changes 
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with classification and diagnostic states brings insight into the biologic nature of 
aggressive melanoma.  With these results, clinicians are presented with information to 
aid diagnosis and prognosis for patients suffering from melanoma.     
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CHAPTER II 
 
MALDI IMS OF MELANOMA: SAMPLE PREPARATION, CELLULAR 
TARGETING, AND PROTEIN IDENTIFICATION 
 
MALDI IMS of biological tissues generates both spatial and molecular information 
from a single experiment.  When arraying an entire tissue, one can group data collected 
from different regions to obtain an average proteomics signature for the cell types that it 
represents.  Questions such as “What proteins accurately characterize and model 
behavior for this disease?” or “What proteins are over expressed when transitioning 
from benign to aggressive disease?” require an accurate representation of the proteins 
from each disease state.  When examining a sizeable cohort of tissue samples for 
biomarker discover, high lateral resolution MALDI IMS can generate an overabundance 
of information and slow analysis process.  For instance, a small melanoma tumor of 4 
mm diameter would contain over 500 data points if imaged at 150 µm.  The same 
representative proteomic signature can be obtained by strategically analyzing 15-20 
data points.  This strategy, termed histology-directed MALDI IMS, integrates 
pathological analysis and the spatial capability of MALDI IMS to target a small number 
of specific, representative cellular regions.52   
Conversely, tissue microarrays (TMA) combine representative tissue regions of 
numerous samples into a high density array where a single MALDI imaging experiment 
can sample 80 or more unique specimens.  In TMA‟s, several benefits of histology 
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directed profiling are largely diminished and a traditional uniform imaging array is often 
optimal.  Here, we describe the protocol for MALDI IMS by histology directed analysis 
and of tissue microarrays for high throughput protein data collection for our use in 
melanoma classification and biomarker discovery.  
 
Histology Directed MALDI IMS Protein Acquisition of Fresh Frozen Tissue 
Histology directed MALDI profiling, originally described by Cornett et al,52 was 
used to collect intact protein information from a cohort of fresh frozen melanoma tumors 
and control lymph nodes.   Here we have slightly modified the workflow and the 
following sections elaborate on the necessary details for tissue preparation, sample 
storage, cellular targeting by pathology, image co-registration, derivation of matrix 
printing coordinates, and accurate matrix printing for automated MALDI data acquisition.  
Each of these considerations is essential in deriving rich, accurate protein profiles from 
specific cellular regions of interest.  The design here is specific to a workflow for 
proteomic analysis of a sizable cohort of fresh frozen tissue specimens.   All conditions 
are optimized for targeting accuracy and protein detection sensitivity.  The purpose and 
strength of the technology used here is to improve throughput and ensure that proteins 
are obtained from the proper cellular regions. 
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Fresh Frozen Tissue Preparation 
Lymph node metastases were collected from 82 melanoma patients at the time 
of regional lymph node dissection. 17 control, cancer-free lymph nodes were obtained 
from patients undergoing partial colectomy for benign disease.  All samples were frozen 
in liquid nitrogen and stored at -80 C until analysis. 
For each tissue specimen, three 12 µm serial sections were cut on a cryo-
microtome.  The first and last tissue sections were thaw-mounted onto a gold coated 
target plate for MALDI analysis.  The center tissue section was thaw-mounted onto a 
glass microscope slide, stained with hematoxylin and eosin (H & E), and 
photomicrographed at with an optical microscope scanner (Mirax, 3D Histech, Hungry).  
The total sample set spanned 15 MALDI plates containing over 200 tissue sections.  
The MALDI plates were immersed in 70% and 90% ethanol (EtOH) for 20 sec each to 
remove abundant lipids, salts, and dehydrate the tissue.60 
Each target plate was allowed to air-dry and marked with 4 fiducials.  Then a 
2400 dpi image was acquired of the whole plate on a optical scanner.  Each plate was 
then stored at -80 C under nitrogen until matrix application.  A pathologist, Dr. Robert 
Low, examined each H & E photomicrograph and selected melanoma foci regions of 
200 µm in diameter, corresponding to the size of a matrix spot.  Each marked H & E 
image was aligned to its two serial sections on the MALDI target plate image and the 
pixel coordinate center of each marked spot and 4 fiducials was saved in a .cnt file.   
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Accurate Cellular Targeting 
The MALDI target plate was loaded into a Portrait 630 acoustic robotic spotter 
(Labcyte, Sunnyvale, CA) and the pixel coordinate file uploaded into the Portrait 
software.  Using the four fiducials, the pixel coordinates were translated into matrix 
printing locations.  For each imported printing coordinate, ~180 pL droplets of 20 mg/mL 
sinapinic acid (SA) in 60/40/0.2 v/v/v acetonitrile/water/trifluoroacetic acid 
(ACN/H2O/TFA) were printed in 6 successive iterations of 10 drops, and allowed to dry 
between each iteration.  The resultant dried matrix spots were approximately 200 µm in 
diameter.  The number of droplets and iterations were translated from optimization 
experiments performed on a piezo-driven inkjet spotter, the ChIP-1000 (Shimadzu) to 
maximize both signal intensity and number of peaks.  In general, improved protein 
signal is obtained by using more drops per iteration with fewer iterations, as opposed to 
fewer drops per iteration with more iterations.   This allows additional time for the 
solvent to extract analyte from the tissue, at the cost of a slightly wider resultant dried 
matrix spot.  
To determine the propagated error in the histology directed workflow, an error 
analysis was performed.  Significant translational errors can be introduced when 
collecting tissue sections and thaw mounting them onto the MALDI plate and glass 
slide.  If the tissue sections are not completely flat, the tissue edges will curl or regions 
in the center may fold together during thaw mounting.  This may result in alignment 
error between tissue sections on the MALDI plate and to the H&E section.  Extreme 
care is taken to minimize this effect via careful tissue handling as well as adjustments 
during the alignment process.   
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The greatest source of error in the entire process of selecting and spotting matrix 
occurs during the image overlay of the H&E section with the image of the scanned 
MALDI plate.  The MALDI plate containing the two serial sections to be overlaid is 
scanned at 2400 dpi (1 pixel = 10.58 µm) on a flat-bed scanner.  Image overlay is 
accomplished by rigid scaling the H&E image (which contains the selected regions of 
interest) onto the section on the MALDI plate image.  Because the outline of the tissue 
may fold or tear (both on the glass slide and MALDI target), interior tissue features 
along with the tissue outline are used for alignment where possible.  This alignment 
error is difficult to measure as each sample is unique, but measurements of internal 
features show an overall error of 3 pixels or 31.74 µm or less.  After all tissue sections 
are aligned, the pixel coordinates of all pathologist marked regions of interest and 
fiducial points are saved as a .cnt file.   
The final step in the process involves importing the pixel coordinates into the 
matrix spotter and then printing matrix to these coordinates.  The Portrait 630 spotter 
has an internal scanner that scans the MALDI plate at a maximum of 1200 dpi (20 µm 
/pixel).  The pixel coordinates of the 3 fiducial points on this 1200 dpi image are cursor 
selected. The software then scales the imported pixel coordinates from the 2400 dpi 
image to the selected fiducial points.  The coordinates of the regions of interest are then 
scaled based on the fiducial scaling.  A single pixel error in selecting the fiducials from 
the 1200 dpi image results in a potential spot importing error of 21 µm.  The final 
positional error source is from the printing accuracy of the spotter itself.  The printing 
accuracy is calibrated by printing a test array of matrix and aligning the print coordinate 
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with the center of the actual printed spot, which again, is limited to the 1200 dpi pixel 
size of 21 µm. 
To calculate the total propagated error from these steps, 
 e4 = (e1
2+e2
2+e3
2)1/2 = (322 + 212 + 212)1/2 = 44 µm.   
Thus, when the pathologist selects 200 µm regions of interest, he was instructed to 
allow a 50 µm buffer around the region that contained the same cells of interest.   
 
Protein Data Collection and Processing 
The coordinates of the positions of each dried matrix spot were transferred to an 
Autoflex II TOF (Bruker Daltonics, Billerica, MA) equipped with a Smart Beam laser.59  
MALDI spectra were auto-acquired from each matrix spot in linear mode using the auto-
execute software in Flexcontrol (Bruker Daltonics).  The relevant instrument settings 
were:  ion source 1 (20 kV), ion source 2 (18.65 kV), lens (6.85 kV), real time smooth 
(High), detection (m/z 2000 – 70000).  A total of 500 spectra were summed for each 
spot using the Random Walk raster pattern, with no evaluation criteria.  These settings 
were optimized for maximum MS resolution and sensitivity between 5-15 kDa, where 
the majority of protein peaks were detected.   
The spectral variability in MALDI analyses can arise from several different 
sources.  Variability in matrix crystallization and laser fluency can affect the overall 
intensity of the final spectra.59  Robotic matrix deposition used here dramatically 
reduces matrix crystal variability56  , especially compared to manual matrix deposition, 
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and as a further control, only one matrix solution was made and aliquoted for each 
MALDI target plate.  Laser fluence and number of laser shots were held constant 
throughout all data acquisition.  The laser fluence value chosen was a compromise 
between detector saturation of the most abundant signals and detection of low 
abundant signals. 
Shot-to-shot spectral variability due to crystal variations, detector saturation, 
laser-beam profile, random noise, and chemical noise is minimized and signal-to-noise 
is improved by summing a total of 500 laser shots at each matrix spot.  Dark-current 
from the detector (i.e. the signal produced without analyte present) is removed by only 
accumulating signals above the measured dark current value.  Overall intensity 
variations, mass shifts, and the high background noise in the baseline of the low mass 
range are adjusted for by spectral processing using total-ion current (TIC) normalization, 
internal calibration, and baseline subtraction using ProTSMarker (Biodesix, Steamboat 
Springs, CO) and ClinProTools (Bruker), see chapter 3.   
After accounting for the systematic and random error from both sample 
preparation and data acquisition, we can confidently assign spectral changes as a result 
of differences within the tissue region probed.  Spectral changes observed in peak 
intensities or the presence/absence of peaks are a direct consequence of the analytes 
in that region. 
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Enzymatically Altered Protein Acquisition of FFPE Tissue 
Formalin fixed paraffin embedded (FFPE) tissue microarrays (TMA) have been 
used to archive various tissue samples.  Formalin preserves the tissue by extensive 
chemical cross-linking between proteins and effectively halts postmortem enzymatic 
proteolysis.61, 62  Fixation preserves the tissue architecture and morphology, allowing 
fixed tissues to be stored for decades usually in paraffin.  During fixation, formaldehyde 
causes the formation of unstable hydroxymethyl groups, which react with other amino 
acid groups forming methylene bridges, predominantly with arginine, tyrosine, and 
lysine.  A  reversal of the chemical cross linking, termed antigen retrieval, is 
accomplished by heating in a buffer solution.62  High density arrays of numerous tissues 
can be constructed by arranging cores of various tumors into a paraffin block.  These 
tissue microarrays (TMAs) can contain several hundred unique tissues in a single block, 
making them ideal for high throughput analysis of large cohorts.   
Intact protein analysis of formalin fixed tissues remains largely unviable for 
MALDI MS due to insufficient control of and limited understanding of the antigen 
retrieval process.62  This is due to the high level of mass specificity obtainable with 
current MS instrumentation, where proteins are often measured with 1 Da mass 
accuracy and the various fixation reactions and side reactions coupled with incomplete 
reversal make protein correlation and identification by intact mass all but impossible.    
Recently, MALDI IMS has been adapted to investigate peptide profiles of FFPE 
TMA‟s by enzymatic digestion prior to MALDI analysis.63  Here we detail the protocol 
used to acquire peptide profiles from formalin fixed melanoma TMA‟s and full size fixed 
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tumors.  While a histology-directed approach is viable, the TMA is already in a high 
density array, and thus more effectively sampled by simply placing a trypsin array 
across the cores. 
 
FFPE Tissue Preparation 
Two 80 core FFPE TMA‟s were acquired from Folio Biosciences containing 
primary and metastatic melanoma and normal skin (ARY-HH0086 and ARY-HH0193).  
Each core was 1.5 mm in diameter and fixed in 10% buffered PBS neutral formalin for 
24 hours, dehydrated with gradient ethanol, cleared with xylene, and embedded in 
paraffin.  All samples were mounted onto ITO-coated conductive glass microscope 
slides.   
Tissues were first deparaffinized by a series of xylene and ethanol washes as 
follows.  The tissue was twice immersed in 100% xylene for 3 minutes, followed by 
successively lower ethanol washes of 100%, 95%, 70% for 1 min each.  Finally, the 
tissue was twice hydrated in pure H2O for 3 minutes.  Antigen retrieval was 
accomplished by pressure heating the slides in a 10 mM Tris buffer solution for 20 min 
at 95 C.  The slides were cooled to room temperature and a series of four dilutions to 
100% H2O was used. 
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On Tissue Digestion 
Proteins were digested into peptide fragments using the basic procedure outlined 
by Groseclose et al.63  Trypsin Gold-Porcine (Promega, Madison, WI) was diluted to 1 
µg/µL in 50 mM acetic acid, divided into 100 µL aliquots, and stored at -20 C until use.  
Trypsin aliquots were activated by addition of 500 µL of 100 mM ammonium 
bicarbonate (AMBIC) and 60 µL acentonitrile (ACN), bringing the trypsin concentration 
to 150 ng/µL.  The matrix solution was immediately put into the Portrait 630 and spot 
deposited across the TMA/tissue.   The trypsin solution was deposited in 1 drop 
iterations at 250 µm lateral spacing over 40 repeats.  For the TMA, the tryspin array was 
roughly 110 x 80, allowing more than 15 minutes between repeats.  Smaller arrays will 
require at least 3-4 minutes between repeats to allow adequate drying times.  It should 
be noted that, unlike traditional in-solution tryptic digestions, on-tissue digestion does 
not reduce and alkylate, meaning the cysteine disulfide bonds will remain intact. 
After 40 iterations, the TMA was placed into a humidity chamber at 37 C 
overnight.  This incubation period significantly improves the digestion of skin and 
melanoma samples.  After incubation, the TMA was re-inserted into the Portrait 630 and 
the reagent changed to 10 mg/mL CHCA matrix in 50/50/0.5 v/v/v H20/ACN/TFA.  The 
matrix solution was printed across the same array using 1 drop iterations of 50 passes, 
where the matrix was placed exactly onto the digested spots. 
Overnight incubation of the trypsin prior to matrix application was compared to no 
incubation using serial sections of TMA HH0193, Figure 7.  In general, the peptide 
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spectra of overnight incubation showed 30-50% more peptides compared to no 
incubation.  This gives ample time for the trypsin to further digest proteins in the TMA.  
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Peptide Data Collection and Processing 
Three corners of the printed matrix array were used to calibrate the positions of 
each dried matrix spot in an Ultraflex II reflectron TOF (Bruker Daltonics, Billerica, MA) 
equipped with a Smart Beam laser.  MALDI spectra were auto-acquired from each 
matrix spot in reflectron mode using the auto-execute software in Flexcontrol and 
FlexImaging (Bruker Daltonics).  The relevant instrument settings were:  ion source 1 
(25 kV), ion source 2 (23 kV), lens (6.85 kV), reflectron 1 (29 kV), reflectron 2 (24 kV) 
,real time smooth (off), detection (m/z 600-4000).  A total of 1000 spectra were summed 
for each spot using the Random Walk raster pattern, with no evaluation criteria.  The 
laser fluence was optimized for S/N and held constant through all acquisitions.  Similar 
adjustments for dark current, matrix crystal variations, and intensity variations were 
implemented as in the intact protein analysis.  TIC normalization, alignment, and peak 
detection were done using FlexAnalysis and ClinProTools software packages (Bruker 
Daltonics, Bellira, MA).   
Matrix was removed from the TMA and whole tissue sections using two 95% 
ethanol washes.  The TMA was then stained using H&E.  Although slight tissue 
morphology disruptions were observed from the MALDI IMS procedure, the majority of 
the tissue remained intact and was sufficient for histological analysis.  Spectra collected 
from tumor regions were grouped and separated from non tumor regions for biomarker 
analysis.   
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Protein Identification 
 
LC Separation and Digestion of Intact Proteins 
MALDI MS produces mass specific data of the intact protein species; however, 
the m/z alone is often not sufficient to positively identify the protein, as the biologically 
active protein may have undergone post-translational modifications.  Robust protein 
identification is routinely achieved through protein separation/isolation, proteolytic 
digestion, sequencing of peptides by LC MS/MS, and matching the peptides to genome-
based protein databases.  The MALDI peaks confidently identified using this strategy 
are shown in Supplemental Table 2, with the unique peptides found and % coverage, 
and the PTM‟s that result in the final biologically observed mass.  The results show that 
this workflow was suitable for many of the proteins above ~9 kDa.  Proteins of MW < 6 
kDa are difficult to identify from a complex mixture on a 1-D gel or identify by directly 
digesting the mixture due to the low number of observable peptides generated.   
Proteins were identified using an adaptation of the procedure previously 
outlined.44, 64  A sample of tissue (~50 mg) was mechanically homogenized in 1 mL of 
TPER (Pierce) solution on ice and the soluble protein concentration determined using a 
Bradford analysis and diluted to 200 mg/mL in 98/2/0.1 H2O/ACN/formic acid (FA).  The 
mixture was separated on a Vydac C8 RP HPLC column, using a 96 minute gradient 
flowing at 0.5 mL/min.  Fractions were collected every minute on a 96-well plate and 
dried.  The 96-well fractions were reconstituted in 5 µL of 60/40/0.2 v/v/v ACN/H2O/TFA 
and 1 µL from each well was spotted onto a MALDI target plate.  SA matrix (20 mg/ml 
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60/40/0.2 v/v/v ACN/H2O/TFA) was mixed on the MALDI target plate and allowed to dry 
and then analyzed on an Autoflex II linear TOF in an autoxecute mode.  The fractions 
that contained protein peaks of interest (i.e. with m/z values matching those observed 
from tissue) were further purified on a tricine gel (Pierce, Rockford, IL), the bands 
excised, in-gel digested with trypsin (Promega, Madison, WI), and the peptides 
analyzed by nano-HPLC MS/MS using a C18 capillary column attached to an HCT ion 
trap (Bruker Daltonics, Billerica, MA).  Results were searched using the ipi-human 
database on SEQUEST and proteins containing at least 2 unique peptides or more than 
15% sequence coverage were considered positive. Modifications, including removal of 
initiator methionine, N-terminal and interior acetylations, disulfide bridges, and signal 
peptide removal, were accounted for to derive the final biological mass observed on 
tissue.  Proteins identified with two or more unique peptides are shown in Table 3.  
Several proteins were identified by a single peptide comprising a significant portion of 
the protein and are provided here as highly probable ID‟s and a basis in future 
identifications, Table 4.  
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Top-down Intact Proteins by MALDI TOF/TOF 
Several low-molecular weight proteins were identified without LC separation 
using a MALDI TOF/TOF  top-down approach.65, 66  To improve sensitivity, a small 
section of tissue was homogenized in 60/40/0.2 v/v/v ACN/H2O/TFA and immediately 
spotted onto a MALDI target plate.  DHB matrix (40 mg/mL in 50/50/0.2 
MeOH/H2O/TFA) was mixed with the solution on plate and allowed to air dry.  SA and α-
cyano matrix were tested, but were not as effective in isolating and fragmenting intact 
parent ions (data not shown).  Linear MS spectra from the tissue homogenate were 
compared to the spectra obtained by direct tissue MALDI analysis to ensure homology.  
Proteins of interest were isolated and fragmented directly from the complex protein 
mixture using an Ultraflex II TOF/TOF (Bruker Daltonics) in LIFT mode.  Resultant 
MS/MS spectra were searched using MASCOT from the BioTools software (Bruker 
Daltonics) with variable modifications of N-terminal acetylations and identifications with 
“extensive homology” considered significant.    
 An example of the top-down MALDI fragmentation and identification from a 
complex mixture is shown in Figure 6, where m/z 4748 was isolated, fragmented, and 
identified as a cleaved form of thymosin β-4 that lacks the 2 C-terminal amino acids.  
The close proximity signal m/z 4737 was likewise isolated, fragmented, and identified as 
a thymosin β-10 with the 2 c-terminal amino acids absent.  Full forms of TYB4 (m/z 
4964) and TYB10 (m/z 4936) were also isolated, fragmented, and identified.   In the 
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case of the ions representing proteins with 2 C-terminal amino acids removed, the 
protein database did not display this modification.   
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Figure 9.  Top-down identification of m/z 4748 (mono-isotopic m/z of 4745) by MALDI 
TOF-TOF.  A) MALDI spectra of tissue homogenate, with in-source LIFT cell isolation of 
m/z 4748.  B) MALDI MS/MS spectra of m/z 4748.  The protein was identified as 
thymosin β-4 with the 2 c-terminus amino acids missing.  The final MW is given by: 
5053 –M (131) –ES (277) + Acetylation (42) = 4748 Da).   
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Identification of Peptides from FFPE TMA’s 
Several peptides from human FFPE TMA‟s were previously identified by 
Groseclose, and here, were confirmed by accurate mass MALDI FT-ICR MS (Apex, 
Bruker Daltonics, Table 4.  Additional peptides from the on-tissue digestions were 
identified in a similar manner to the top-down tandem MALDI using both alpha-cyano 
and DHB matrix spots, Table 5.  Isolation and fragmentation of ions was performed 
directly from the TMA, in contrast to a spotted homogenate.  In searching MASCOT, 
collagen peptides contain numerous hydroxylated proline groups and the variable 
modification was included.   
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CHAPTER III 
 
INTACT PROTEIN CHARACTERIZATION OF STAGE III MELANOMA LYMPH NODE 
METASTASES BY MALDI IMS  
 
Patients with melanoma metastatic to the regional lymph nodes exhibit a range in 
tumor progression, survival, and treatment.  Current approaches to stratify patients with 
this stage of disease are predominantly clinical and histological methods.  Molecular 
classification thus far has focused almost exclusively on genetic mutations.  In this 
study, proteomic data from 69 melanoma lymph node metastases and 17 disease free 
lymph nodes acquired by histology-directed MALDI IMS were used to classify tumor 
from control lymph node and to molecularly sub-classify patients with stage III disease.  
From these data, 12 survival associated protein signals and 3 recurrence-associated 
signals in the acquired mass spectra were combined to generate a multiplex molecular 
signature to group patients into either poor or favorable groups for recurrence and 
survival.   
 
Introduction 
Despite continued research and increased public awareness, melanoma accounted 
for an estimated 62,000 new cancer cases and 8,400 deaths in 2008 in the U.S. 4  
Melanoma arises from melanocytes, the melanin (pigment) producing cells found in the 
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skin.  Melanocytes occupy the basal layer between the dermis and epidermis, and are 
normally singly distributed with each melanocyte surrounded by multiple keratinocytes.   
Melanocyte growth and production of melanin upon exposure to ultraviolet light (UVL) is 
tightly regulated by these surrounding keratinocytes via highly structured dendritic 
processes.5, 67  Tumorigenesis of the melanocytes requires independence from 
keratinocyte regulation and the suppression of pro-apoptotic and anti-proliferative 
pathways.68    
Staging of melanoma was established by the 2002 American Joint Committee on 
Cancer (AJCC) Melanoma Staging Committee and is determined by the depth of the 
primary tumor, ulceration, and presence or absence of regional lymph node (Stage III) 
or distant metastasis (Stage IV). 12, 13 Early stage melanoma is easily diagnosed and 
highly curable, but late stages are resistant to therapy with survival rates often below 
15%.14   The first line of treatment for all stages of melanoma is surgical resection, when 
feasible. In advanced cases, systemic treatment with α-interferon or dacarbazide, or 
high-dose interleukin-2 are used, although response rates are low, toxicity is high, and 
long-term survival benefits are limited.14, 69, 70   
The significant variability in survival of patients with stage III melanoma (24-70% 5-
year survival) points to an insufficient understanding of the heterogeneity of the disease.  
Clinical and pathological prognostic factors for survival of patients with stage III disease 
include tumor thickness, ulceration and mitotic rate of the primary tumor, and the 
number and size of involved lymph nodes.  These factors, however, offer limited 
biologic or mechanistic understanding of the disease.  So far, molecular classification of 
melanoma has largely focused on identifying genomic mutations.71  Several mutations 
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among key cell signaling pathways have been shown in metastatic melanoma, including 
BRAF15 and NRAS of the MAPK pathway, CDKN2A, and APAF-1.22, 72  However, 
proteomic based molecular classification, which provides information about relative 
protein abundances and post-translational modifications (PTM‟s), is largely missing. 
Here, histology-directed MALDI IMS has been used to identify proteins found in 69 
lymph nodes involved by metastatic melanoma and 17 control lymph nodes free of 
tumor.  From the proteomic signatures obtained directly from the tissue, a molecular 
classification of tumor and control lymph tissue was generated that could differentiate 
normal and malignant tissue.  In addition, lymph node metastases from 62 patients with 
stage III melanoma were analyzed to identify proteins associated with survival and 
recurrence.  The protein signatures that correlate with these outcomes were confidently 
identified.  Beyond diagnostic and prognostic value in assessing melanoma 
progression, these protein signatures may provide valuable insights in the choice of 
optimal treatment strategies for individual patients. 
 
Distinguishing and Classifying Control LN and Stage III Melanoma by Protein 
Signatures 
 
In determining proteomic differences between cancer free lymph nodes and tumor 
regions infiltrating lymph nodes, two goals were outlined:   
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Goal 1: Determine protein expression differences between stage III tumor infiltrating 
lymph nodes and control lymph node 
Goal 2: Develop molecular classifiers to accurately distinguish tumor from control 
Each goal incorporated related, but unique software and statistics approaches for peak 
detection and processing.  It is important to note that the same raw data was used for 
both analyses. 
 
Protein Expression Differences between Control LN and Tumor 
For this workflow, raw data was converted and processed for incorporation into a 
significance analysis of microarray (SAM) package.  Raw data was first exported from 
the Bruker data format to two column .txt files using in-house software.  The summed 
spectra from each matrix spot were pre-processed individually using ProTSMarker 
(Biodesix, Steamboat Springs, CO).  The program performs baseline subtraction, 
spectral smoothing, peak alignment, peak detection, and total-ion current (TIC) 
normalization using user input values across the entire m/z range to improve the local 
estimation and is an updated version of the software previously described.73  Each 
spectrum was first pre-processed using input data from  31 peaks ranging from m/z 
3300 – 15300 that were present in >95% of spectra.  The FWHM of each peak was 
measured, and a multiplied by 4 and 10, per the manufacturer‟s recommendation, for 
baseline and smoothing for input into ProTSMarker.   The software then uses those 
values for smoothing, baseline subtraction, peak detection, and spectral alignment 
specific to those mass ranges.   
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Outlying spectra of low signal-to-noise, spectra with less than 30% of peaks 
present, or spectra dominated by hemoglobin (m/z 15,127 and 15,865) were removed.  
The remaining processed spectra were averaged within each patient to generate a 
single representative spectrum composed of >15 discrete matrix spots (melanoma 
specific regions) from each patient.  Post processing of the averaged spectra used 
centroid peak detection and area under the curve (AUC) measurements to generate a 
feature table containing all patients, each protein, and the AUC of each for the entire 
cohort.    Data was collected for analytes up to 70 kDa, with observable high molecular 
weight peaks corresponding to 42, 53, and 66 kDa (tentatively assigned as actin, 
vimentin, and albumin). However, generally above m/z 25000 the number and intensity 
of peaks observed was not sufficient to reliably judge a significant change in expression, 
and thus features above this m/z were excluded.  The averaged spectra were used in 
the SAM and survival statistical analysis.  The peak detection algorithm of ProTSMarker 
detected a total of 155 protein features in the m/z range 2000 – 40000.   
The feature table was evaluated using a 2 class SAM test.  Protein peaks that 
differed by more than 2-fold area under the curve (AUC) with a false-discovery rate 
(FDR) of (p=0.001) were considered significant. The SAM results showed 71 protein 
peaks that exhibited at least a 2-fold intensity difference between control LN and 
melanoma lymph node metastases.  A spectral view of the results is shown in Figure 10 
and a complete list of all significant proteins in Table 2. 
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Both tissue types consistently display intense peaks at m/z 11307 (histone H4), 
m/z 14007 (histone H2A), and broad peaks at m/z 13780 (histone H2B) and m/z 15345 
(histone H3) (Figure 2).  The four histone species form the chromatin complex that 
organizes DNA in a highly ordered, compact form.  Modifications to the histone species, 
specifically acetylations and methylations, are a highly regulated process that controls 
the accessibility of chromosomal regions and to the transcription machinary.74, 75  
Multiply acetylated forms of histone H4 (m/z 11307, 11349, and 11391) and H2A (m/z 
14007, 14049, and 14091) are easily distinguishable, but the H2B and H3 histones are 
observed as broad, unresolved peaks, no doubt due to multiple isoforms and 
methylations.  The histone H3 peak displayed significantly higher intensity in the control 
LN and the triply acetylated histone H2A at m/z 14091 was significantly different 
between the groups with a 2.4-fold increase in the tumor spectra.  
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Proteins peaks observed at higher intensity in the tumor regions included several 
S100 calcium binding proteins (S100 A6, S100 A11, S100 B), macrophage migration 
inhibitory factor (MIF) involved in immune response and inhibition of p53 mediated 
apoptosis76, heat shock protein 10 kDa 1 (HSP10) that is involved in regulating protein 
folding with HSP60 and in increasesing the anti-apoptotic Bcl-xl and Bcl-2 proteins77, 
and the antioxidant thioredoxin78.  Measurements of high levels of MIF and HSP10 
suggest activation of cell survival pathways. 
 Few melanoma tumor biopsies contained significant portions of surrounding 
lymph node tissue.  These were imaged by traditional MALDI IMS and displayed the 
majority of significant protein differences between the tissue types, Figure 12.  Although 
only 2 histone species were significant by 2-fold intensity from the SAM analysis, all 4 
histone peaks consistently displayed higher intensity in control lymph node and tumor 
adjacent lymph node compared to melanoma foci regions. 
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Molecular Classifiers of Control LN and Tumor 
Beyond describing individual protein variations between the groups, the protein 
signatures were used to generate classification models to accurately distinguish each 
tissue type (Figure 3).  The ClinProTools software (Bruker) package was utilized for 
spectral smoothing, baseline subtraction, peak detection, alignment, and TIC 
normalization.  Unlike ProTsMarker, ClinProTools uses general processing parameters 
that apply to the entire mass range.  This significantly increases usability and ease of 
use at the cost of high customizability.  Again, outlying spectra of low signal-to-noise, 
spectra with less than 30% of peaks present, or spectra dominated by hemoglobin (m/z 
15,127 and 15,865) were removed.   
From the ClinProTools software, Principal Component Analysis (PCA) and 4 
classification models were used to differentiate the two groups.  The PCA simplifies 
multidimensional data by combining similar or redundant information into fewer 
variables (usually 3).79  In this case, each protein or m/z is an independent variable 
generating a data set of m-dimensions.  The PCA will plot the dataset in m-dimensional 
space and generate orthogonal vectors that maximize the data spread or variance.  
Here, the top 3 vectors or principal components are used to plot the dataset in 3D 
space, graphically displaying the spread in groups, Figure 12 A.  The variation across 
the tumor samples compared to the compact distribution of the lymph nodes is visually 
represented.  This result was compared to a multidimensional scaling (MDS) plot of the 
top 23 discriminatory peaks from the SAM analysis, Figure 13 B.   In this procedure, the 
dimensionality is reduced from 23 to 3, where the distance in 3D space is proportioinal 
to the distance in 23D space. 
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Molecular classification between the control lymph node and lymph node 
infiltrated tumor were generated using 4 models in the ClinProTools software: Genetic 
Algorithm (GA), Support Vector Machine (SVM), Supervised Neural Network (SNN), 
and Quick Classifier (QC).  Each model selects and weights a combination of protein 
peaks that provide high distinguishing ability between the two groups and are briefly 
described.  The genetic algorithm derives from evolutionary survival in which the best 
peak clusters are combined into a new feature and the poor clusters are discarded.  
This process is iteratively repeated until the optimal peak combination is found.80  The 
SVM algorithm generates a plane that optimally separates two data sets.  Peaks are 
ranked by their ability to separate into either side of the plane and the top peaks 
selected [V. Vapnik, "Statistical Learning Theory", Wiley and Sons, New York, 1998].  
The SNN algorithm maximizes the distance of multiple local peak clusters specific to 
each group, as opposed to 2 clusters in SVM.  Clusters that provide greater separation 
are prioritized over those with low separation [B. Hammer, M. Strickert and T. Villmann 
"Supervised Neural Gas with General Similarity Measure", Neural Processing Letters 21 
(1), 21-44 (2005)].   Finally, the QC algorithm generates an average spectrum for each 
group with weighted p-values for each peak.  Based on the peak weights, spectra are 
categorized into either group along with a likeliness value. 
The result of each model is shown in Table 10.  Each of the classification models 
showed a high recognition capability, the lowest still recognizing and correctly 
classifying nearly 90% of the patients.  In all cases, 100% of control LN samples were 
correctly identified and the wrong recognition was from the tumor samples.  This missed 
classification can be visualized in the PCA where some of the tumors appear close to 
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the LN region.  The robustness of each model was additionally evaluated by cross-
validation (20% leave out, 10 iterations), with results very near the original recognition.   
 
 
Table 7.  Recognition capability of 4 classification models to distinguish melanoma and 
control lymph node.  Cross-validation comprised 10 iterations of 20% leave out.  
- 70 - 
 
 
Correlating protein changes to patient survival and recurrence 
Proteomic data from the histology directed MALDI IMS workflow was additionally 
used to determine markers of tumor aggression.  Patient survival and time to recurrence 
information were used as markers of tumor aggression.  Towards this end, two goals 
were outlined: 
Goal 1: Determine individual proteins that correlate with patient survival and disease 
recurrence and investigate their biologic role. 
Goal 2:  Develop models from the protein data to accurately group patients by their 
clinical outcome. 
 
  Training and Test Set 
The feature table used in the SAM procedure containing AUC of each protein 
across the cohort was used in the survival and recurrence analysis.  Of the original 69 
lymph node metastases, 7 patients were treated for palliative reasons and excluded. 
Melanoma biopsies were acquired in two batches, the first comprising the training set 
and the second the test set, Table 8.  Individual proteins associated with survival and 
time-to-recurrence in stage III melanoma lymph node metastases were first determined 
in the training set by using a univariate Cox-proportional hazard (CPH) model81, with an 
individual p-value of less than 0.05 considered significantly associated.   
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The Cox proportional hazard model is a sub-set of survival plots that deal with 
identifying hazardous features that are related to the likelihood of dying.  In this model, 
the hazard function is a result of multiplicative covariants (i.e. features) and is given by 
H[(t), (X1, X2, ..., Xm)] = h0(t)*exp(b1*X1 + ... + bm*Xm) 
where the hazard value h at time (t) is a function of the covariants (X1…Xm) and h0(t) is 
the baseline hazard.  The value of this model is that the baseline hazard h0(t) need not 
be known or defined fully.  In applying this model to proteomic data, each protein 
feature can be examined as an independent covariant.  By dividing two hazard functions 
with only one variable increasing we obtain a hazards ratio for that particular covariant.  
For example, if we compare the hazard ration of λ1 at X1 and λ2 at X1+1of b1 where:  
λ1= h0(t)*exp(b1*X1 + b2*X2... + bm*Xm) 
λ2 = h0(t)*exp(b1*(X1 +1) + b2*X2... + bm*Xm) 
then the hazard ratio λ1/λ2 = exp (b1), when all the other values are fixed.  Each protein 
signal can be examined as a covariant along with other standard covariants (age, sex, 
gender, treatment, etc). This gives us a ranking of protein intensities of increasing 
association to the hazard function, i.e. survival time. The analysis was performed using 
the freeware R program (Version 2.10), and the source code along with a description of 
each line is provided for reference. 
Of the 155 proteins detected in the training set, 7 were significantly associated 
with patient survival and 2 with recurrence (p < 0.05, Table 8).The significant proteins 
were weighted by their univariate predictive ability and combined into a single 
compound predictor (CP), for both survival and recurrence, with m/z 16789 (p = 0.056) 
included to allow at least 3 proteins for a recurrence compound predictor.   
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Table 8.  Patient stage III melanoma biopsies were received and analyzed as 2 different 
cohorts for training and test sets (A).  Protein data from each patient biopsy was 
collected by histology directed MALDI IMS.  A CPH model evaluated each protein 
individually in the training set to determine proteins associated with survival (B) and 
recurrence (C).  “Poor” effect denotes a worse patient prognosis as the protein intensity 
increases, and likewise, “favorable” denotes a better prognosis as the protein intensity 
increases.   *Indicates protein form observed has a c-terminal truncation. 
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Patients in the training set were ranked by their CP score and a division by CP 
scores of “poor” (Med. Survival/Recurrence < 12 months) and “favorable” (Med. 
Survival/Recurrence > 12 months) was made (p = 0.0014), Figure 4A top.  Proteins with 
a „poor‟ effect increased intensity with worse patient prognosis, and conversely, those 
with a „favorable‟ effect increased with better patient prognosis.  The set of proteins and 
their weighted predictive CP score was used to group the Test set into both a “poor” and 
“favorable” group using the same CP score range.      
For survival, a division from the ranked CP scores of “poor” (median survival ≤ 12 
months) and “favorable” (median survival > 12 months) was made   The set of proteins 
and their weighted predictive CP score was used to group the Test set into both a “poor” 
and “favorable” group using the same CP score range (p = 0.06), Figure 13A bottom, 
with the “poor” group having a median survival of roughly 12 months, in line with the 
prediction.   
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Figure 13.   Training and test patient groups were used to generate and validate 
survival and recurrence compound predictor (CP) protein signatures.  The CP was 
generated from the sum of the significant proteins in the training set, weighted by the 
proteins predictive ability, for both survival and recurrence.  A) top: The patients in the 
training set were ranked and divided by their CP score into 2 groups: “poor” (Med. 
Survival ≤ 12 months) and “favorable” (Med. Survival > 12 months).   A) bottom:  CP 
range for “poor” and “favorable” survival was evaluated in the test set, showing 
comparable median 12 month survival in the “poor” group.  B) top: Recurrence CP 
scores divided the training set into “favorable” (Med. Rec. > 12 months) and into two 
poor groups: “poor” (Med. Rec. = 8 months) and “poorer” (Med. Rec. = 5 months).  B) 
bottom:  Recurrence CP score evaluated in the test set, which successfully showed 
comparable “poor” (Med. Rec. = 9 months) and “poorer” (Med. Rec. = 4 months) 
groups, in line with the predicted score.  *The “favorable” group in the recurrence test 
set was omitted for clarity, see text.  
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The same general procedure was applied to the training and test set using 
patient recurrence time.  However, in addition to the “favorable” group (median 
recurrence > 12 months), the recurrence CP scores divided the training set into 2 poor 
groups: “poor” (median recurrence ~ 8 months) and “poorer” (median recurrence ~ 5 
months), p = 0.0249 Figure 13B top.   The recurrence CP values from the training set 
were evaluated in the test set, resulting in very comparable “poor” (median recurrence ~ 
9 months) and “poorer” (median recurrence ~ 4 months) groups, p = 0.152 Figure 1B 
bottom.  The “favorable” group in the test set contained too few patients to draw a 
reliable conclusion from, and was omitted from the graph for clarity. 
Univariate Analysis of Pooled Cohort 
While limited in number, the ability of the predictive CP score to group patients in 
the test set according to their median survival and recurrence was an encouraging 
validation of the method and gave us confidence in combining the training and test sets 
into a single cohort to achieve greater statistical power, Table 9.  Protein markers from 
the combined data set were obtained using the same univariate CPH model and p value 
cutoff as the training set.  As an additional test, a bootstrap method was employed that 
randomly sampled the combined patient data with replacement, ranked each biomarker 
using the CPH model on the new sampled data, and repeated the procedure 1,000 
times. 
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.   
Table 9.  The training and test set cohorts were pooled and reexamined using both a 
univariate CPH model and a resampling with replacement boostrap analysis.  *Indicates 
protein form observed has a c-terminal truncation. 
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In both the univariate CPH and the bootstrap of the pooled data, all of the original 
survival and recurrence protein markers from the training set were found, with the 
exception of m/z 4283.  The pooled data analysis was able to identify 6 additional 
proteins associated with survival.  These new markers were weighted and combined 
into a CP to rank each patient, and the set divided into upper 33% (“unfavorable”, red 
diamond) and lower 33% (“favorable”, blue triangle) groups for both survival and 
recurrence.  Each patient from the dichotomized groups was plotted using the value of 
two significant proteins, m/z 4049 and 4737 for survival and m/z 16791 and 12275 for 
recurrence, Figure 14, A-B top.  The result shows the spread of patients from two 
proteins, and the survival and recurrence trends for those groups (p = 0.0001 and p = 
0.0095 respectively), Figure 5, A-B bottom.     
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Figure 14.  Graphical representation of proteins related to survival and recurrence. 
Patients with a high compound predictor (unfavorable outcome, red diamond) were 
plotted with patients having a low compound predictor (favorable outcome, blue triangle) 
for both survival and recurrence. A) Top: Plot of the weighted intensity of 2 proteins 
associated with poor survival, m/z 4049 and m/z 4737 (TYB-10, modified).  A generally 
better prognosis is observed as both proteins decrease, as shown in the survival plot 
(bottom).  B) Top: Plot of the weighted intensity of 2 proteins associated with favorable 
recurrence outcome, m/z 16791 (Calmodulin) and m/z 12275 (CyC), with better 
prognosis as the intensity of both proteins increase, displaying a longer time to 
recurrence (bottom).   
  
- 79 - 
 
 
Discussion 
 
Melanocytes are derived from the neural crest and the predominant cells present 
in lymph nodes (B and T lymphocytes) are derived from the bone marrow, so it is not 
surprising that the protein signatures from control lymph nodes and melanoma lymph 
node metastases exhibit drastically different characteristics.  Of the 123 protein features 
observed, 57 displayed over a 2-fold intensity difference between the groups.  Most of 
the differentially expressed proteins were observed at higher intensity in the tumor 
specimens, with a smaller number of proteins expressed at higher intensity in control 
lymph nodes.  This is a common feature of the tumor cellular regions and may be from a 
culmination of rapidly dividing cells, increased cellular density in the tumor regions, and 
proteins that are specifically over-expressed in the tumor cells.  The goal of establishing 
protein classifiers that distinguish melanoma-involved lymph nodes from control lymph 
nodes is to improve the targeting, diagnosis and stratification of patients with stage III 
disease.   
Several proteins observed in tumor regions are calcium binding proteins, 
specifically the S100 family of m/z 10091 (S100A6, Calcyclin), m/z 10625 (S100B), and 
m/z 11653 (S100A11, Calgizzarin) as well as calmodulin (m/z 16791).  Beyond Ca2+ 
homeostasis, the S100 proteins are involved in numerous intracellular processes, 
including regulation of protein phosphorylation, cytoskeleton dynamics, cell growth and 
differentiation, and inflammatory response.82  Calcyclin interacts with numerous 
proteins, including S100B, and its expression is observed in many cancers.83 The 
presence of these S100 proteins has been previously observed by MALDI IMS as 
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increased in aggressive human gliomas50  and wound healing mouse tissue84.  From 
the survival analysis, we identified m/z 10091 (S100A6) as an unfavorable marker, a 
protein previously identified as a potential marker for aggressive melanoma by mRNA 
analysis of human xenografts in mice.85    The bootstrap analysis found calmodulin as a 
favorable prognostic marker for patient recurrence.  Calmodulin is ubiquitously 
expressed in cells, where it binds to and regulates numerous proteins involved regulator 
pathways, including protein kinases and phosphatases as well as in cytokinesis.86  The 
protein has been implicated as a prognostic marker in lung cancer87 and shown 
important in cell adhesion of uveal melanoma cells,88 but its specific association in 
prolonged recurrence is unknown.    
The IHC stain for S100 is routinely used as a histologic marker to confirm the 
diagnosis of melanoma, but the antibody is strongly associated with S100B and less-
specific to other various S100 proteins.11  In analyzing the tissue via MALDI IMS, each 
of the detected S100 proteins can be monitored individually from a single experiment.  
This spatial and protein selectivity allows a combination of the observed S100 features 
to generate a multiplex signature to improve diagnostics by reducing the influence of 
less melanoma specific members of the S100 family.  For example, although S100B, 
S100 A6, and S100 A11 display consistent, near 5-fold higher intensity in the melanoma 
regions, the intensity of S100 A8 (m/z 10745) is identical between groups and the 
putative S100 A1 peak (m/z 10458) is absent in control LN and 1/3 of the tumor 
samples but is clearly seen in the remaining 2/3 of tumors.  Each of the S100 proteins is 
involved in a wide variety of cellular functions82, and the ability to monitor these 
individually by MALDI IMS will be advantageous in understanding their biological roles.          
- 81 - 
 
The recognition of cytochrome C (CyC, m/z 12275) as a protein that may correlate with 
the behavior of melanoma is intriguing.  Cytochrome C expression was significantly 
more intense in melanoma versus control lymph nodes, possibly due to its role in 
energy production functions in the inner mitochondrial membrane as part of electron-
transport chain.89 However, increase in m/z 12275 correlated favorably to longer time to 
recurrence, consistent with a role in the intrinsic apoptotic pathway.  When released into 
the cytosol, cytochrome C binds with APAF-1 and initiates the caspase cascade that 
ultimately leads to apoptosis.90  The association between cytochrome C expression and 
increased time to recurrence suggests that melanomas with high expression may have 
an intact apoptotic pathway and thereby be more responsive to therapy or progress 
more slowly.  Cytochrome C is a nuclear gene that does not gain its heme group until 
reaching the mitochondria.  Interestingly, the holocytochrome c (containing the heme 
group, +615 Da) and not the apocytochrome c (lacking heme group) is required to 
initiate apoptosis.  The form identified in the direct tissue analysis is m/z 12275, which 
contains the heme group (the apocytochrome c species presumably at m/z 11660 was 
not observed, possibly obscured by the S100 A11 peak m/z 11651).  The increase in 
m/z 12275 initially suggested a potential functioning apoptotic pathway in patients with 
increased time to recurrence; however, with IHC staining for activated caspase-3, only a 
weak correlation was observed between tissue areas high in m/z 12275 and activated 
caspase-3(data not shown).  An increased expression of other anti-apoptotic proteins, 
such as MIF and HSP10, may be suggestive of a more vigorous anti-apoptotic activity.     
One of the more unexpected results is the association of cleaved proteins in 
patients with low survival.  Of the 12 proteins related to survival, 3 are modified forms 
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with two C-terminus peptides missing/removed.  Each di-peptide set is unique and the 
cleaved forms were observed at non-uniform ratios to the intact protein.  Ubiquitin (Ub, 
m/z 8565) appears with its cleaved form missing the C-terminus GG (Ub-GG, m/z 8451) 
and has been observed in several biological processes.91  Both thymosin β-4 (TYB4, 
m/z 4964) and thymosin β-10 (TYB10, m/z 4936) were found to have similarly cleaved 
forms (TYB4-ES, m/z 4748) and (TYB10-IS, m/z 4737).     The thymosin β proteins 
sequester actin monomers within the cell, inactivating polymerization until needed.92  
The full length thymosin β proteins have been routinely observed across species in 
MALDI tissue analysis37, 46, 50, 93 and both thymosin β-4 and  β-10 have been implicated 
in the metastatic progression of melanoma.94, 95  The full length thymosin proteins are 
often over expressed in metastatic cells, where their over expression causes additional 
actin sequestration, a less rigid cytoskeleton, and allows more motility in the cell.96, 97  
To our knowledge, cleaved forms of TYB4 and TYB10 have not previously been 
associated with metastatic melanoma or other cancer.  The modified forms of the 
thymosin proteins have been observed (TYB10 natively and TYB4 artificially) and in 
both cases, though the N-terminus is predominantly responsible for actin binding, the 
truncated C-terminal form causes a small, but significant loss in binding.98, 99 While an 
increase in full length thymosin proteins corresponds to metastatic cell potential by 
means of increased actin sequestration, our analysis suggests that a slight reduction in 
actin binding amongst metastatic tumors correlates with a more aggressive tumor.  This 
may give the cells increased rigidity thereby promoting their survival in the foreign lymph 
environment.  Intact forms of thymosin β revealed no significant difference between 
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control and tumor groups or in relation to survival/recurrence, and interestingly, neither 
did the actin associated proteins cofilin-1 (m/z 18415) or profilin-1 (m/z 14968).      
Histone H4, H2B, and H3 were found to positively correlate with patient survival.  
Histone H4 is observed as two clearly resolved isoforms of m/z 11307 and 11349.  
Pesavento  et al showed that these are comprised from the removal of the initiator 
methionine, an N-terminal acetylation, and a dimethyl modification on residue K20 for 
m/z 11307 and an additional acetylation on residue K16 for m/z 11349.100  The 
respective isoforms were shown to comprise 69% and 17% of the total H4 forms during 
the G0/S0 phase.  As the cell cycle passed into G2/M phase for cell division, the relative 
values fell to 59% and 11%, respectively.  In relation to our findings, the positive 
correlation of these two peaks with survival would clearly be in line with a less rapidly 
dividing tumor.  Decreased intensity of the two H4 peaks indicates significant cell growth 
in the tumor and would thus correlate unfavorably with survival.   Overlapping isoforms 
of various methylation and acetylation PTMs in histone H3 and H2B register as broad 
unresolved MALDI peaks, with respective widths of 150 Da and 75 Da, significantly 
wider than the 30 Da widths of nearby hemoglobin peaks.  Improved mass resolution to 
deconvolute these multiple isoforms will be required for understanding the specific role 
in survival.  
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CHAPTER IV 
 
PROTEOMIC CLASSIFICATION OF FFPE MELANOMA BY in-situ ENZYMATIC 
DIGESTION AND WITH MITF EXPRESSION 
 
 
 Fresh frozen tumors remain ideal for extracting rich protein information in their 
native forms.  Yet, long term preservation of excised tissue has for years incorporated 
the use of chemical fixatives that alter the native stats of proteins.  The most widely 
used of these, formalin, cross-links proteins making traditional direct tissue MALDI IMS 
largely unviable.  Proteomic analysis of formalin fixed tissues with MALDI IMS has 
recently been developed using localized enzymatic treatment allowing direct analysis of 
the proteolytic products.  Here, this technology is adapted for investigation of formalin 
fixed melanoma tissues, both in tissue microarrays and whole tumor sections in an 
effort to generate proteomic data for classification models of melanoma sub-types.  
Additionally, the proteomic data was correlated with modern IHC technology to connect 
MALDI IMS with a key melanoma oncogene MITF. 
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Introduction 
 Formalin fixation remains the most common and robust method for long term 
storage and archival of biological tissue samples.  The preservation of biopsies and 
whole organs via chemical fixation with formalin remains the status quo for most 
hospitals and clinical research facilities worldwide.  This fixation eliminates protein auto 
degradation and thus tissue degradation by generating an array of chemical cross links 
between proteins while preserving the tissue architecture and morphology.61  Whole or 
representative tissue volumes are often embedded into paraffin blocks following fixation, 
termed formalin fixed paraffin embedded (FFPE), to further protect the tissue and to aid 
in tissue sectioning. Preserved tissues can be sectioned decades later, and analyzed by 
histological analysis allowing clinicians and researchers the ability to carry out long term 
patient follow-up and investigate patient groups in a retrospective analysis.   
 Although the tissue remains viable for analyzing morphological features, the 
extensive cross-linking of proteins (and RNA/DNA) severely inhibits molecular analysis 
of the tissues.  This prevents traditional antibody based immunohistochemistry (IHC) 
and the majority of proteomic and genomic analyses by making the specific protein and 
gene binding sites inaccessible or possibly compromised.  Approaches to reverse 
formalin fixation for these types of analyses have made headway using a variety of 
chemical approaches, generally termed antigen retrieval.62  The most common 
procedure remains the use of heat and pressure in a buffer solution to hydrolyze the 
cross-linked bonds.   Once partially reversed, the tissue can be analyzed by antibodies, 
gene analysis, and by LC MS/MS.101 
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  In cancer investigations, high n values (i.e. numerous patient samples) are 
required to develop accurate conclusions and robust biomarkers.  The large consortium 
of archived FFPE tissue samples provides an excellent source high volume studies.  
However, collecting individual tissue samples for each patient in a cohort and analyzing 
them one at a time is not only slow and time consuming, but increases the likelihood of 
introducing discrepancies from tissue to tissue.  To address this issue, FFPE samples 
have been collected from numerous sources and combined into a high-density tissue 
microarray (TMA).102-104  In this approach, representative cylindrical “cores” of different 
tissue samples are collected with a micro punch of 0.6-1.5 mm diameter.  Each core is 
then arranged into a dense array by insertion into a paraffin block.  Once sectioned and 
mounted on a traditional microscope slide, hundreds or more unique samples can be 
analyzed thereby significantly improving throughput. 
The use of MALDI IMS technology for such high density tissue arrays has great 
potential to understand the complexity and heterogeneity of melanoma tumors.   
Primary melanoma has several distinct subtypes clinically diagnosed based on the 
location, such as in acral lentiginous melanoma (AL), uveal, and mucosal.  Cellular 
growth patterns are also used to classify primary melanoma as either superficial 
spreading or nodular.10  These subsets of melanoma have been found to house a set of 
unique mutations (Table 10) that lead to their arrival, and have different response rates, 
though the exact reasons are debated.105  Notable mutations include BRAF, NRAS, and 
KIT.  The overwhelming argument for this diversity is in genetic mutations arriving from 
non-sun induced (AL and mucosal) compared to sun induced, specifically differentiating 
chronic sun exposure from non-chronic.  While these findings clearly improve our 
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understanding of the disease, the variability in mutations is readily apparent.106, 107  
Furthermore, several of the mutations, such as BRAF and NRAS, lie along the same 
molecular pathway in addition to being present in non-malignant moles. 
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The clinical subtypes of melanoma display heterogeneous mutated pathways.  
Apart from distinguishing the origins of the various subtypes, identifying the biology of 
the tumor and its local environment is critical, particularly for improved patient care.  
TMA‟s in combination with MALDI IMS present a feasible platform to approach this 
problem by combining large patient numbers, investigative proteomics, and the 
integration of parallel technologies like immunofluorescence(IF).  The spatial information 
and selectivity of MALDI IMS and IF is particularly intriguing, as results of both can be 
directly overlayed for very specific comparisons of regionally distinct cellular groups.  It 
is toward this end that we approach the analysis of melanoma TMAs with the following 
goals: 
Goal 1: Determine molecular features that distinguish the various subtypes of 
melanoma, including primary, acral lentiginous, mucosal, and lymph node metastasis. 
Goal 2: Determine molecular features indicative of the tumor biology, independent of 
the clinical subtype. 
Goal 3: Establish a connection of proteomic technology with advanced IHC analysis in 
a high throughput manner. 
To accomplish this goal, two tissue microarrays containing various melanoma 
subtypes and control skin were acquired.  With the present diversity of melanoma, 
TMA‟s represent the most promising method of effectively combining proteomics, IHC, 
and histological diagnosis in a high throughput manner. 
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Cohort and Data Processing Methods 
Two melanoma TMA‟s, HH0193 and HH0086,  were purchased from Folio 
Biosciences containing 80 tissue cores of 1.5 mm diameter.  The tissue cores were 
grouped into one of 5 classes, comprised of 4 melanoma subtypes and control skin as 
follows: 1) acral lentiginous (AL), 2) lymph node metastases (LN), 3) mucosal, and 4) 
primary tumors and 5) normal skin. The category of „primary‟ included non-acral and 
non-mucosal melanoma tumors infiltrating the skin and no distinction was made 
between superficial spreading, nodular, lentigino, or the degree of chronic sun exposure 
as the clinical information was not available from Folio Biosciences, though these 
subdivisions have shown some significance.107  Additionally, it has been suggested that 
these classifications are non-specifc, difficult to reliably substantiate, and should be 
abandoned or reevaluated altogether.108  ALM, mucosal, and primary categories were 
comprised of stage I/II tumors and LN as stage III. TMA HH0193 comprised 16 
mucosal, 14 acral lentiginous, 19 primary skin, 23 lymph node metastases, 4 ocular, 
and 4 distant metastases melanoma tumors.  TMA HH0086 contained 5 mucosal, 15 
acral lentiginous, and 14 primary skin melanoma tumors and 8 normal skin tissues each 
in duplicate.  The ocular and distant metastases were excluded due to limited sample 
numbers along with several cores which demonstrated aberrant cellular morphology.  Of 
the duplicate cores, the one containing the largest area of tumor and/or least amount of 
tissue tearing, necrosis, or significant blood cell involvement was chosen. The normal 
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skin was, unsurprisingly, clearly distinct from the melanoma tumors, and based on the 
smaller sample numbers and analysis regions, were included with their duplicates.  The 
remaining cohort comprised 23 acral lentiginous, 18 lymph node metastases, 18 
mucosal, and 28 primary skin melanoma tumors and 13 normal skin tissues, Table 11.   
 
Table 11.  Demographic of two TMA‟s containing melanoma subtypes and control skin 
tissue cores. 
 
Digested protein data collected from these samples, and detailed in chapter 2, 
was used in all of the classification analyses.  Directly after MALDI IMS analysis, the 
matrix was removed and the TMA was stained with H&E.  Image alignment of the H&E 
image with the IMS image was done using Fleximaging software (Bruker).  Histological 
analysis of each core was performed, and the MS spectra from regions corresponding 
exclusively to melanoma locations were exported as csv files, processed and averaged 
into a single representative spectrum using ProTSMarker.  All classification, spectral 
and gel visualization, and PCA plots were computed with these averaged spectra using 
the ClinProTools software (Bruker). 
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Distinguishing Melanoma Subtypes 
 Previous analyses in distinguishing melanoma subtypes has focused primarily on 
genetic mutations.105, 109  Interestingly, class divisions do not show consistent, 
distinguishable mutations, but rather populations that posses higher percentage of a 
particular mutation.   
 
Primary Tumor vs. Normal Skin 
 A baseline performance of the MALDI IMS platform for distinguishing melanoma 
tumors was generated using the division between normal skin and primary skin tumors.  
These tissue types were clearly distinguishable by both histology and MS peptide 
profiles and provide a measure of the „best performance‟.  Tryptic peptide MS spectra 
from 28 primary tumors (red) and 13 normal skin cores (green) were directly compared, 
Figure 15.  Significant variations were observed in most of the identified collagen alpha 
(I) and (II) peptides.  Using 4 classification model, the two tissue classes were 
distinguished and classified with nearly 95% accuracy, Figure 15.  PCA generation 
revealed significantly distinct regions and the two groups could be successfully 
differentiated based on two peptides, m/z 1105.6 (actin) and m/z 1477.7 (collagen), 
Figure 16.  In the two peptide comparison, several of the normal skin samples grouped 
similarly to the primary tumors.  Further investigation revealed that these were normal 
skin tissues “adjacent” to cancer, though no tumor was evident.  Several of the collagen 
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peptides were significantly diminished in the 3 cancer adjacent normal skin compared to 
normal skin, Figure 17, specifically collagen alpha-1 (I) containing 0 hydroxyl proline 
residues and collagen alpha-1 (III).  While 3 samples are far from sufficient in statistical 
power, the results encourage further investigation.     
 The identification of collagen alpha-1 as a potential marker for infiltration and 
demarcation of tumor boundaries is promising.  Collagen makes up the majority of the 
extracellular matrix (ECM), the fibrous network that provides rigidity and anchorage to 
cells.  Collagen is found in over 20 distinct types, though type I, II, III, and IV make up 
the majority and are fibril forming.110  Collagen is sythesised as a procollagen, a water-
soluble protein in the endoplasmic reticulum and secreted from the cell where it 
undergoes enzymatic removal of N-propeptides and C-propetides.  Once removed, the 
collagen chains assemble into fibrils composed of a triple helix of 3 collagen monomers 
offset by 234 ammino acids.  Collagen monomers may join as identical chains, as in 
type III collagen composed of 3 alpha-1(III) chains, or different, as in type I composed of 
2 alpha-1(I) and 1 alpha-1(I).  Key to the generation and rigidity of the triple helix is the 
repeating polypeptide sequence Gly-X-Y, where X and Y are any amino acid, but 
posses a high percentage of proline/ hydroxyproline.  Beyond providing structural 
support, collagen fibrils provide binding sites for numerous compounds and are 
essential in cell growth and motility.111  Additionally, the ECM must often be degraded to 
allow cell movement, typically via secreted matrix-metalloproteinases (MMP).17  The 
collagen peptides displayed here are type I and III, save a single type IX, and 
characterize the extracellular environment. 
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Primary Melanoma vs. Lymph Node Metastases 
 As previously stated, early onset melanoma remains largely curable if treated 
early, while metastatic tumors, even to the regional lymph nodes, presents a life 
threatening disease.  Towards understanding the alterations between local primary 
melanoma and metastatic disease, the peptide signature of 28 primary tumors was 
compared directly to 18 lymph node metastasis, Figure 18.  The spectra were 
considerably more similar to each other than was observed in the normal skin and the 
accuracy of the classification model dropped to ~80%.  Yet, PCA and two peptides (m/z 
1105.6 and 815.5) did reveal a high level ofseparation between the 2 classes, Figure 
19.   
The major peptide disparities between the groups were the multiple histones and 
collagen species, as shown in the results of a 2-class SAM (1.5 fold change and 
FDR<0.0001), Table 13.  The results clearly show a drop in the presence of various 
collagen peaks as the melanoma metastasizes and an increase in the various histone 
peaks.  The results were not uniform across the two classes, but rather showed a higher 
population of cores containing an increase or decrease of these peptides (Figure 20-
11).  Figure 20-21 details gel plot views of all 46 tissues aligned to the average MS 
spectrum of the two classes.  The average spectrum shows the two histone and three 
collagen peptide peaks shown are at a significantly different intensity for the two- class 
comparison.  However, investigation of individual all cores reveals the classes contain a 
mix of tumors containing a range of intensities for these peaks.  This phenomenon was 
observed throughout the remaining class comparisons and the MITF analysis. 
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Primary vs. Acral vs. Mucosal 
 Previous research has shown a slight variation of genetic mutations between AL, 
mucosal, chronic sun damaged and non chronic sun damaged tumors (grouped as 
„primary‟ in our analysis).105  This has been attributed to the differences in how these 
melanoma subtypes acquire their mutations, whether from UV damage (primary) or 
non-UV related acquisition (AL and mucosal).   
 In our analysis comparing peptide signatures from these three groups, significant 
heterogeneity within each group was observed.  PCA and classification models were 
not able to distinguish these groups with any reasonable level of confidence.  Model 
classifications were below 50% accuracy.  While the origins and sites of genetic 
mutations may be distinct, the peptide signature indicates the active biology of the 
tumors and their local environment offer distinguishing characteristics.   
 
Tissue Grouping by Function 
Based on previous findings, significant heterogeneity within each melanoma 
subtype exists.  While initially the multiple subtypes have a probability of originating 
from different genetic mutations, the proteins present are indicative of the cellular 
activity, regardless of the original trigger mechanism.  Several peptide signals averaged 
within clinical subgroups were similar, but the clinical classes displayed a 
heterogeneous collection of tissues, several displaying a particular peptide as intense 
yet other tissues in the same clinical class showed low intensity levels of the same 
peak. The MALDI spectra suggested that each clinical class was composed of subsets 
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of melanoma cells.  In addition, the spectra suggested more similarity of similar subsets 
across clinical classes than within.  A list of the most prominent and intense peaks 
across the 4 melanoma classes was compiled and the percentage of high expression as 
seen across all samples and within each clinical subtype is shown in Table 14.  
Peptides considered “highly expressed” were double the intensity of a set of the lowest 
peaks, termed baseline expression.  The chart displays the heterogeneity of cores, 
across clinical subtypes.   For example, m/z 1477.7 (collagen alpha-2 (I)), displayed 
high expression in 58% of AL tumors, 24% of LN tumors, 50% of mucosal, and 38% of 
primary tumors but only low to moderate expression in the remaining cores.  While a 
general similarity between AL and mucosal tumors are similar (58% and 50%, 
respectively) compared with primary (38%) and particularly to LN (24)% can be found, I   
hypothesize that cores displaying high expression are similar, independent of the 
clinical subtypes.   
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Two classes of peptides contributed the greatest diversity across the cohort: 
histone and collagen, Table 14.    A single peptide of each group was chosen to sort 
and dichotomize the tissue cores: m/z 944.53 (histone H2A) and 1477.7 (collagen 
alpha-2 (I)).  When sorted this way, related histone and collagen peptides displayed a 
similar expression profile trend, Table 15. 
 
Table 15.  Peptides that show similar intensity trends when sorted by either m/z 944.35 
(histone h2a) or m/z 1477.7 (collagen). 
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Grouped by Collagen alpha-2 (I) 
One class of peptides contributing to the heterogeneity of melanoma samples 
comprised the collagen tryptic peptides.  One of the collagen peaks, m/z 1477.7 
(collagen alpha-2(I)) was selected and the cohort sorted by the measured intensity of 
m/z 1477.7 and dichotomized into „low m/z 1477.7‟ (or „low collagen‟) and „high m/z 
1477.7‟ (or „high collagen‟) groups.  When separated by a single collagen peptide the 
remaining collagen peaks generally followed the same intensity distribution trend.  The 
result was that the „high m/z 1477.7‟ dichotomized group also housed melanoma cores 
containing high intensity of nearly all of the identified collagen peptides as well as a set 
of unidentified peptides, Table 15.  The average MS plot of the two classes is shown in 
Figure 22 along with the model classification accuracy of near 80%, Figure 22.  The 
PCA and two-peptide trend display a high degree of class separation, Figure 23.   
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Grouped by Histone H2A 
The most intense of the histone peptide signals was chosen to sort data across 
all 4 melanoma classes, m/z 944.53 histone H2A, in a similar manner.  After sorting, the 
cohort was dichotomized into „low m/z 944.35‟ (or „low histone‟) and „high m/z 944.35‟ 
(or „high histone‟).  The majority of other histone peptides as well as fibrinogen and actin 
displayed similar intensity trends, Table 15.  MS spectral averages of each group and 
the results of 4 classification models are shown in Figure 24.  Greater than 80% 
accuracy in distinguishing the two groups was observed, on the order of observations 
between primary and lymph node tumors and significantly improved from the accuracy 
in classifying acral-mucosal-primary.  Both the PCA and two-peptide comparison show 
a high degree of separation, indicating that the histone peptides collectively represent a 
clinical class-independent subset of melanoma tumors, Figure 25. 
Of particular interest, no direct relationship between separations based on the 
histone or collagen peak was observed.  Each separation and dichotomization produced 
a unique orientation of the melanoma samples.  It is probable that the histone 
separation is indicative of internal cellular function and the collagen levels indicative of 
the tumor microenvironment (see discussion) and the unique separation of each is due 
to the orthogonal functions. 
  
- 112 - 
 
 
- 113 - 
 
  
- 114 - 
 
Integration of MITF IF and MALDI IMS 
 Micropthalmia-associated transcription factor (MITF) acts as a master regulator 
of melanocyte development, function and survival by moderating numerous 
differentiation and cell-cycle progression genes.6  MITF is a transcription factor that 
binds to DNA as a dimer and appears to be regulated by several pathways, including 
WNT, MAPK, and the cAMP/CREB.  Activation of MITF leads to cell cycle progression, 
inhibition of apoptosis, and cell differentiation. 
MITF has shown amplification in 10-20% of primary melanoma cases and is 
associated with a decrease in long term survival.112   However, MITF expression among 
melanomas remains variable, with some advanced disease exhibiting down regulation 
and some exhibiting amplification.   Towards understanding the role of MITF in 
melanoma, we compared MITF immunofluorescence with the MALDI IMS protein data.   
 
MiTF Staining Protocol 
A serial section of TMA HH0193 was stained for MiTF using the following 
procedure.  The slide was first deparrafinized by twice immersing in xylenes for 5 
minutes, followed by decreasing EtOH gradients of 100% EtOH for 3 minutes twice, 
once in 95% EtOH for 2 minutes, once in 70% EtOH for 2 minutes, once in 50% EtOH 
for 2 minutes, and once in ddH2O for 1 minute.  Antigen retrieval of the formalin fixed 
slide was accomplished by immersion in 10 mM sodium citrate.  The slide was 
microwaved at 30% power for 12 min until almost boiling and allowed to cool to room 
temperature.  Finally the slide was washed 3 times in PBS for 2 minutes.  The tissue 
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was permeabilized in PBS with 0.2% Triton-x100 for 10 minutes, washed 3 times in 
PBS for 2 min each, and then blocked by 5% normal donkey serum in PBS with 1% 
BSA for 1 hour at room temperature.  The primary antibody Rabbit-a-MiTF (Sigma) was 
diluted 1:500 in PBS with 1% BSA and reacted overnight in a humidity chamber at 4ºC.  
The tissue was washed 3 times in PBS with 0.1% Triton-x100 for 2 min and then 3 
times in PBS for 2 min each.  The secondary antibody Alexa 594 Donkey-a-Rabbit was 
diluted 1:10,000 in PBS with 1% BSA and reacted for 1 hour in a humidty chamber at 
room temperature.  The slide was then washed 3 times in PBS containing 1% Triton-
x100 for 2 min, 2 times in PBS for 2 min, and a third time in PBS containing 1:10,000 
DAPI and ToPro for 2 min.  The slide was imaged on an Olympus IX81 fluorescent 
microscope using an excitation/emission wavelength of 594/617 nm. 
MiTF is a nuclear gene, so DAPI was used as a control to ensure that only the 
IHC fluorescence observed in the nuclear region was used.  MiTF was scored into three 
categories: 0 = No MiTF, 1 = MiTF above background, 2 = High MiTF intensity.  Scoring 
was done blindly, without any knowledge of any of the tissue classifications.  An 
example of a 2 scoring is shown in Figure 26, where the MiTF and DAPI stains overlay 
perfectly and there is little to no MiTF staining outside the DAPI regions. 
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Tissue cores were grouped into 3 classes according to their scored MiTF 
reading.  Table 16 shows selected proteins that correlated with these groups.  As MiTF 
is only present in ~20% of melanoma and effects several molecular pathways, a uniform 
protein trend corroborating MiTF intensity from 0 to 1 to 2 scoring was not observed.  
However, several of the proteins demonstrated significantly higher intensity in the 
groups.  The viable regions of HH0193 for the MiTF scoring cohort was composed of 64 
tissue cores containing acral, LN met, mucosal, and primary melanoma tumors.  The 
level of MiTF appeared to be independent of melanoma subtype, though mucosal 
tumors showed the highest level of score 2 staining.   
 
Table 16.  Tissue cores analyzed with MiTF immunohistochemistry.  MiTF_0 
corresponds to staining below the background, MiTF_1 distinguishable from the 
background, and MiTF_2 as intense staining.   
 
No distinguishable correlation between melanoma subtype and intense MiTF 
staining was apparent, as in the case with clinical class comparisons.  All cores were 
grouped based on their 0, 1, or 2 scoring independently of the subtype.  MiTF staining 
did not correlate to a uniform intensity of any proteins, an expected result as MiTF 
regulates several cellular functions.  Rather, tissues that showed MiTF staining (score 1 
and 2) contained a greater number of intense peaks of the various histone species and 
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glutathione s transferase as compared to the background (score 0), Table 17.  Several 
peptides demonstrated the opposite trend, notably, m/z 976 (actin), 1067, and 1132.  In 
the previous analysis, grouping all tumors by the intensity of m/z 944.35 (histone H2A), 
an actin peak (1198.8) followed the same trend, but in the MiTF profile, a different actin 
peak (m/z 976.4) showed an opposite trend.  The collagen peaks displayed no 
correlation with MiTF expression, reaffirming a sense that the histone peaks are 
indicative of intra-cellular biology and the collagen indicative of the extra-cellular tumor 
microenvironment. 
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Discussion 
Tissue microarrays present the opportunity to investigate large sample numbers 
and with MALDI IMS in a direct comparison to more traditionsal methods (e.g. 
immunofluorescenc) in an effort to classify with high both cancer and human tissue 
samples.  In the two TMA‟s analyzed by proteomic MALDI IMS, a high degree of 
heterogeneity was observed, both in the cellular architecture and morphology as well as 
in the MALDI IMS and immunofluorescent MiTF staining.  This underscores the need to 
develop high throughput technologies and platforms capable of the large numbers 
required to understand and measure numerous variables.  These include age, gender, 
treatment, stage at original diagnosis, and location of the tumor, genetic mutations, and 
activated oncogenic pathways.  Here, we have focused exclusively on the biology as 
determined by the protein signature levels of tryptic peptides. 
Clinical information for both HH0193 and HH0086 TMA‟s where available to 
group the tissue core on the basis of the melanoma subtype, namely, as acral 
lentiginous, mucosal, lymph node metastasis, primary skin melanoma and normal skin.  
The most notable trend was the decrease in collagen levels from normal skin to primary 
tumor to metastatic tumors infiltrating lymph nodes.  Control skin, here composed of 
mostly the top layers of the skin, displayed very intense levels of collagen I and III, 
nearly an order of magnitude above most primary melanoma tumors.  Histologically, 
control skin is clearly distinguishable from the tumor samples, and the MALDI IMS 
results echoed this high separation with molecular models able to distinguish the groups 
with 95% classification accuracy.  Normal skin is composed of the dermis and 
epidermis, which consist of mainly connective tissue and keratinocytes and relatively 
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few melanocytes, the precursors of melanoma.  In the histological analysis, the majority 
of primary tumors and lymph node metastases engulfed the 1.5 mm tissue core, leaving 
little native dermal/LN architecture, resulting in data collection from tumor regions fully 
equilibrated with their ECM.  The significant drop in collagen levels in the primary 
melanoma tumors signifies the structural rearrangement the malignant melanocytes 
perform during growth.  In primary tumors, the equilibrated ECM content may derive 
either from that formed directly by the melanoma cells or a result of “left-over” ECM from 
the skin.  In either case, the melanocytes have reorganized their micro-environment to a 
condition suitable for their growth.  Continuing this trend as the melanoma metastasizes 
to the lymph nodes, collagen levels drop further.  The lymph node environment is 
significantly different, as the lymphocytes flow freely past each other to exchange 
immunoreactive signals.  While these general trends where observed, a portion of the 
LN tumors displayed significant levels of collagen and several primary tumors low 
levels.  This suggests that certain melanomas may require collagen adhering and 
functioning with the ECM through their integrins to grow successfully while in others that 
pathway has been altered and cells can proliferate without it.  These results are 
intriguing in light of work showing that preconditioning of collagen-I networks by 
aggressive melanoma cells allowed less aggressive cells to develop vasculogenesis, 
functioning more like aggressive cells.113 
One of the peculiar findings was the drop in a set of collagen peaks in normal 
skin that was marked as “cancer-adjacent normal skin”.  While 3 samples is a low 
number to make exhaustive conclusions, the findings are interesting, especially if future 
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experiments show a trend in the melanoma cells to exert a degradation influence on 
collagen beyond just the advancing tumor border.114 
When examining proteomic differences between the 3 stage I/II tumors (acral, 
mucosal, and primary skin), the data was intriguing.  Instead of clear, consistent protein 
differences between the groups, we observed significant variations where a single 
peptide would appear at high intensity intermittently throughout and between classes 
while still showing low intensity in many of the cores.  When analyzing the relationship 
of these peptides, 2 classes of peptides were found that independently sort the tissues 
regardless of their subtype: histone and collagen.   
A collection of histone peptides that make up the chromatin complex, H2A, H2B, 
H3, and H4, were found.  Histone peptides from H2A, H2B, and H3 generally showed 
similar intensity trends, but H4 was not correlated.  This may be due to the low intensity 
and limited number of H4 peptides discovered.  Despite observing histone H4 as a 
positive prognostic marker in our fresh frozen samples, peptides containing the first 21 
amino acids of the protein were not observed, due to 7 tryptic cleavage sites in this area 
alone.  Unlike histones H4 and H3, which exhibit extensive acetylation, methylation and 
phosphorylation in bulk material the H2A forms observed here are interesting in their 
total lack of internal modifications.115  Thus it appears that the levels of histone H2A 
specifically is indicative of the tumor density or of the tumor turn over and not of various 
isoforms or PTMs.  Histone H3 remains extensively modified, more than any of the 
other histone proteins, and thus cannot be readily interpreted based on the few peptide 
fragments shown.  However, the technology is clearly under development to monitor 
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both the independent methylation and acetylation sites as well as their spatial 
distribution throught the melanoma tissue in a high throughput manner.  
When sorted and dichotomized by m/z 944.45 (histone H2A) or m/z 1477.7, 
molecular models successfully classified the „high/low‟ groups with 80% accuracy, 
higher than when the tissues were separated based on clinical subtypes.  Each 
separation was unique, grouping different subsets of cores together.   In addition, m/z 
1198.7 (actin) and 1032.6 (fibrinogen) displayed similar intensity distributions to the 
histone peaks while m/z 1094.5, 1235, 1459, and 2957 show similarity with the collagen 
sorting.  Taken collectively, it appears that the histone collection of proteins is indicative 
of the cellular density and proliferation while collagen represents a portion of the tumor 
microenvironment. 
The results of the MiTF scoring emphasize this conclusion.  With the numerous 
controlling pathways that MiTF regulates, it is not surprising that no single peptide 
uniformly increased in correlation with MiTF IF levels.  In general it is believed that 
increased levels of MiTF correspond to an aggressive tumor, as the protein activates 
proliferative pathways and inhibits cell-cycle arrest.6  The positive and intense MiTF 
scoring tissues possessed a high percentage of tissue cores with more intense histone 
peaks than the level 0 scoring.  This corroborates the conclusion that an increase in 
histone levels is a function of cell growth/density and functionally separate from the 
influence of the collagen matrix.  In addition, glutathione s-transferase (GST) was found 
increased in a higher percentage of MiTF positive tissues.  Glutathione S-transferases 
(GSTs) are a family of isoenzymes that catalyze the detoxification of substrates of 
reactive oxygen species (ROS) via conjugation with glutathione.  GST has been found 
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to be increased in several tumors and specifically, over-expressed in solid tumors 
resistant to drugs.116  Whether these MiTF and GST‟s findings show a causative or 
correlative relationship is unclear, but particularly interesting is GSTs and melanomas 
resistance to drug treatment. 
Our results indicate that melanomas should be classified based on internal cell 
biology (increased histone, MiTF, and GST) and external environments (collagen) and 
our results indicate these trends are independent of traditional clinical classifications.  
Interestingly, these discrepancies are independent of clinical classifications.  
Incorporating TMAs with MALDI IMS in a high throughput, multi-platform approach, we 
may be poised to decipher the biological complexity and persistent low therapeutic 
response rates observed in melanoma. 
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CHAPTER V 
 
CONCLUSIONS AND FUTURE PERSPECTIVES 
 
 
Towards Improved Patient Care 
 
It is clear that patients presenting with malignant melanoma exhibit a 
heterogeneous group of tumor cells, independent of stage and location based clinical 
subtype.  This no doubt contributes to so many treatments for melanoma continuing to 
under-perform.  Toward improved patient care and patient specific customized 
treatment strategies, robust diagnosis of the state of the melanoma cells must be 
determined.  The work detailed here pushes the frontier toward that goal by providing 
proteins that relate to more aggressive stage III disease as well as providing evidence 
and methodology for determining cellular microenvironments and function. 
In stage III melanoma, critical decisions concerning advanced surgical and 
adjuvant treatments must be made.  The results presented give evidence for molecular 
based distinguishing features of more aggressive tumors.  These protein markers 
include proteins implicated in altered cytoskeleton dynamics, in the case of modified 
thymosin beta 4 and 10, as well as measurements of cell cycle progression, in the case 
of decreased acetylated forms of histone H4.  Positive prognostic markers, including 
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cytochrome C show a resistance to of the host to the tumor regions which is ultimately 
insufficient to completely halt tumor growth.  These markers provide distinguishing 
diagnostic and prognostic information on an individual patient basis, while also 
improving our understanding of the complex biology in metastatic melanoma. 
This high degree of complexity manifests in heterogeneous tumors, as shown 
from analyzing melanoma TMS‟s.  Yet, peptide signals measured across the various 
clinical subtypes reveal defining features indicative of the cell biology and its 
microenvironment.  As melanocytes transform into uncontrolled aggressive cells, these 
results show they modify their environment by manipulating the collagen anchorage 
structures around them.  As they invade and establish metastatic colonies in foreign 
tissues, their collagen microenvironment is further reduced.  During this same 
oncogenesis, internal cellular alterations are progressing, shown here as increasing 
levels of several histone proteins.  The changed tumor microenvironment, as measured 
by collagen levels, and indications of cell cycle progression, as measured by histone 
proteins, can independently sub classify tumors with comparable or greater 
commonality compared to traditional location based clinical classification.  The MALDI 
IMS tryptic digestion findings were further directly integrated with IF of MiTF levels, 
confirming the independent classification of histone and collagen levels. 
These two platforms, one generating rich intact protein data from fresh biopsies 
and the other integrating IF and MALDI IMS for large cohorts of fixed specimens, 
provide a powerful base to continue to understand this disease.  As with all developing 
and emerging technologies, future experiments must be done to validate and elucidate 
further the mechanisms involved in the protein markers discovered.  While fresh frozen 
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tissue analysis remains closer to the native tissue, limitations exist with long term 
preservation and scale.  Tissue microarrays, while chemically modified, present a high 
throughput and viable solution to obtaining the sample numbers required to account for 
the large diversity in the scope of melanoma patients.  It is my recommendation that 
detailed in-depth analysis continue to be performed while pushing the mass range of 
detected intact proteins and improving the selectivity of all proteins detected.  Large 
cohort analyses connecting investigative proteomics with established biomarkers, such 
as MiTF, will require high-throughput platforms such as TMAs. 
The protein and peptide signals identified here bridge statistical model 
computation with biologic function.  The top-down identification of two proteins 
containing unregistered C-terminal modifications gives strong emphasis to improving 
platforms to identify proteins in their natural state directly from complex samples.  
MALDI IMS provides a powerful tool in distinguishing different PTM form of proteins, 
and improved identification abilities would benefit tremendously. 
Lastly, while patient confidentiality remains a vital part of medical care, it can 
severly limit research into improved patient diagnosis and prognosis.  In these 
investigations, it was incredibly difficult to obtain samples containing patient follow-up 
information, such as treatment and survival information.  There is a strong push to 
separate tissues in tumor banks from the actual patient, and I strongly encourage 
methods to both ensure patient confidentiality while continuing to provide researchers 
with the necessary information to continue to understand the disease. 
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Future Outlooks: Advancement in IMS 
 
Increasing Analytes by Multimodal Imaging 
 While proteins are the cornerstone of cellular biology and continue to be the 
focus of pharmaceutical targets, they alone do not explain or expound upon the 
complex nature of the cell.  It is clear that as we push forward, we must combine 
multiple analyte detection in diagnosis and prognosis determination, especially in the 
area of investigative research.   
Towards this end, our laboratory is actively engaged in technology to acquire 
images of multiple analytes from single tissue sections using MALDI IMS, Figure 27.  
This multimodal imaging approach has been demonstrated in principle and is shown 
here.  At present, the technology works by sequentially applying matrix, collecting 
MALDI images of the analyte, and matrix removal for the next analyte.  This process is 
done in increasing order of damage to the tissue, beginning with sublimed DHB for lipid 
analysis, SA coating for intact protein analysis, and finally by aggressive tissue 
digestion using trypsin.  From the uniform DHB coating, two lipid images are collected:  
first, lipids that ionize optimally in (+) mode, then offsetting the analysis array and 
acquiring lipids that ionize optimally in (-) mode from the same coating of uniformly 
distributed matrix.  Not only are two distinct imaging data sets collected, but because 
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the matrix layer is sublimed and perfectly uniformly coated, the MALDI images can be 
acquired at very high lateral resolutions, currently on the order of 60 µm. 
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 The matrix application, imaging, and matrix removal are minimally disruptive to 
the tissue.  No solvent is applied, but slight morphological changes are apparent.  To 
remove the DHB coating, EtOH washes that are required for traditional SA images are 
sufficient to remove the matrix, lipids, salts, and effectively dehydrate the tissue for 
intact protein analysis.  Application of SA matrix remains the optimal method for protein 
imaging, which can then be easily removed for a final image of tryptic digestion. 
  The benefit of this multimodal approach in patient care is apparent.  Firstly, the 
multiplex of data provides additional markers for more specific prognostic power.  
Secondly, the ability to determine lipid and protein response from the same regions will 
definitely improve our understanding of the entire biological snapshot.  Finally, because 
these are all taken from a single tissue sections, the technology remains viable with 
limited specimen amounts and allows incredibly tight corregistration of the different 
analyte images without complications that may arise from comparing serial sections, 
such as tissue tearing/shifting or artifacts. 
 Technologies such as these, improve number of biological analytes available in 
generating classification models, distinguishing disease states, and in piecing together 
the function of normal functioning and diseased tissues.  Multiplexing data rich 
technologies such as this are poised to take biological analysis of cancers, including 
melanoma, into the 21st century. 
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